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RÉSUMÉ 
Arrière-plan: les cellules tumorales circulantes (CTC) sont détectables dans de nombreux 
cancers et peuvent être utiles cliniquement pour le pronostic de la maladie, pour mesurer la 
récidive et pour prédire la sensibilité aux medicaments chimiothérapeutiques. Au cours des 
dernières années,  l’études des CTC dans de nombreux cancers tels que le cancer du sein, du 
poumon, du côlon et de la prostate a grandement évolué. Alternativement, il y peu d'études à ce 
sujet concernant le cancer du col de l’utérus (CCU). Objectifs: Notre objectif est d’optimiser le 
processus d'enrichissement des CTC dans le CCU et la détection moléculaire des biomarqueurs 
E6 et E7. Matériel et Méthodes: Dans l’optique de mimer la présence de CTC dans le sang, 
nous avons dilué des cellules cancéreuses CaSki VPH16-positif provenant d’un CCU dans du 
sang humain prélevé sur des volontaires sains. Les CaSki ont été collectées suite à une 
centrifugation par densité avec le Ficoll, la lyse des globules rouges (RBC) et la lyse des RBC 
combinée avec un enrichissement positif et négatif à l’aide de marqueurs de surface cellulaire. 
Les CTC ont été détectées par la mesure d’expression des oncogènes E6 et E7 du virus du 
papillome humain (VPH), de la cytokératine 19 (CK19) et de la cycline p16INK4 en utilisant la 
technique quantitative en temps réel de Reverse Transcriptase-Polymerase Chain Reaction 
(qRT-PCR). Pour valider notre méthode de détection des CTC in vivo, nous avons recruté dix 
patientes atteintes d’un CCU VPH16 positif et six contrôles sains. Résultats: Dans le modèle 
de dilutions de cellules CaSki, la lyse des RBC seule ou combinée avec l'enrichissement négatif 
ou positif suggèrent des limites de détection de 1 CTC par mL de sang pour tous les 
biomarqueurs moléculaires utilisés. La sensibilité de détection est accrue lors de l'utilisation de 
l’enrichissement positif et négatif en réduisant le bruit de fond causé par les monocytes sanguins. 
Contrairement aux oncogènes E6 et E7, les marqueurs CK19 et p16INK4A ont été détectés chez 
des individus sains, les niveaux d'expression de base appropriés doivent donc être déterminés 
avec précision par rapport aux patientes CCU. Le gradient de densité par Ficoll a une limite de 
détection de seulement environ 1000 cellules par mL de sang. Enfin, les CTC ont été détectées 
dans 2/10 patientes en utilisant le marqueur CK19. Cependant, ces patientes étaient négatives 
pour les oncogènes E6/E7. Le marqueur p16INK4A était exprimé au même niveau dans tous les 
échantillons (CCU et normaux). Conclusion: Notre étude suggère que les oncogènes E6 et E7 
du VPH16 sont les marqueurs biologiques les plus sensibles et spécifiques en qRT-PCR pour 
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détecter les CTC dans le modèle de dilution de cellules de CCU dans le sang. Chez les patientes 
atteintes d’un CCU de stade précoce, seulement CK19 a révélé la présence potentielle de CTC, 
ce qui suggère que ces cellules sont rares à ce stade de la maladie. 
 
Mots clés: cancer du col de l’utérus, cellules tumorales circulantes, RT-qPCR, E6 et E7, CK19, 
p16INK4A, enrichissement immunomagnétique, détection moléculaire. 
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ABSTRACT 
Background: Circulating tumor cells (CTCs) have been detected in many cancers and are used 
in multiple clinical applications including disease prognosis, tumor recurrence prediction and 
prediction of tumor sensitivity to chemotherapeutic drugs. Studies in most major solid cancer(s) 
(breast, lung, colon and prostate) are progressing rapidly, but there has been very little progress 
concerning uterine cervical cancer (UCC).Objective: our aim is to optimize enrichment 
processes and the molecular biomarker-based detection of human circulating tumor cells (CTCs) 
in uterine cervical cancer (UCC). Material & Methods: To mimic CTCs in patients, we 
designed an experimental spiking model where the CaSki HPV16-positive UCC cell line was 
serially diluted and spiked into human blood collected from healthy volunteers. CaSki CTCs 
were enriched using either Ficoll density centrifugation, red blood cell (RBC) lysis or RBC lysis 
combined with cell surface markers negative or positive enrichment. CTCs were detected using 
real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) to measure 
the gene expression of human papillomavirus (HPV) viral oncogenes (E6 and E7), cytokeratin 
19 (CK19), or the cyclin dependent kinase inhibitor p16INK4A. Finally, ten HPV16- positive UCC 
patients and six healthy controls were recruited to validate CTCs detection in vivo. Result: In 
the spiking model, RBC lysis alone or combined with negative or positive enrichment suggests 
detection limits close to 1 CTC per mL of blood for all molecular biomarkers used. The 
sensitivity of detection increased when using positive and negative enrichment probably by 
reducing the peripheral blood mononuclear cell-derived RNA background. Unlike HPV 
oncogenes, CK19 and p16INK4A were detected in normal individuals, thus appropriate basal 
expression levels need to be accurately determined compared to cancer patients. Alternatively, 
Ficoll density gradient had a detection limit of only about 1000 cells per mL of blood. Finally 
CTCs were detected in 2/10 patients using CK19. None of the patients had E6/E7 transcripts 
and p16INK4A was expressed at similar level across all samples (cancer and healthy). 
Conclusion: qRT-PCR of HPV16 E6 and E7 is the most sensitive and specific biomarker used 
to detect CTCs in the spiking model. In early disease UCC patients, only CK19 revealed the 
presence of CTCs suggesting that these cells are rare at that stage of the disease. 
Keywords: uterine cervical cancer, circulating tumor cells, qRT-PCR, E6 and E7 oncoprotein, 
CK19, p16INK4A, immune-magnetic enrichment, molecular detection.   
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CHAPTER I : INTRODUCTION  
1.1 Circulating tumor cells and the induction of metastasis 
Metastasis is a complex process that involves interplay between tumor cells and the hosting 
organs. The invasion-metastasis cascade consists of multiple steps as shown in Figure I-1. 
Tumor cells found within the blood stream are defined as circulating tumor cells (CTCs) [1, 2]. 
At the primary tumor site, multiple signaling pathways function to promote cellular 
proliferation, growth inhibition, survival, and invasion, as well as induce tumor angiogenesis, 
all of which facilitate the metastatic process [3]. Tumor cells proliferate in response to various 
growth factors; such as transforming growth factor-beta (TGF-β), insulin-like growth factor-1 
(IGF-1), and epidermal growth factor (EGF) that activate the RAS, mTOR, and PI3K-AKT 
signaling pathways [4, 5]. Once tumors reach a critical size where the local blood supply does 
not meet cellular metabolic demands, hypoxia-inducible factor (HIF) is released to promote the 
expression of the angiogenic proteins vascular endothelial growth factor-A (VEGF-A) and 
angiopoietin-2 (Ang-2) [6]. This event results in the formation of neovasculature characterized 
by high permeability, abnormal structure, and variable blood flow [7-9]. In addition, the co-
influence of TGF-β and HIF promotes a process termed epithelial-mesenchymal transition, 
where epithelial tumor cells acquire a mesenchymal phenotype that allows them to invade, 
migrate, and gain cancer stem cell-like traits [10-12]. Once through the basement membrane, 
tumor cells can reach the blood and lymphatic vessels and travel to distant organ sites where 
they can then move out. Cells within this founder population undergo mesenchymal-epithelial 
transition (MET) and begin to form metastatic tumor colonies.  
Studies suggested that hematogenous spread is an early event that can occur prior to 
diagnosis of the primary tumor [13]. Multiple studies have reported that the detection of CTCs 
in early-stage cancer is associated with poor prognosis [14]. CTCs have been identified in many 
epithelial cancers, including breast, colon, lung, and prostate, and have recently demonstrated 
prognostic value [15-18]. Other applications of CTC detection include assessing treatment 
response, genetic mutations, drug resistance screening and selection of patients for adjuvant 
systemic treatments [19]. 
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Figure I.1. Invasion-metastasis cascade. Angiogenesis initiates to meet the metabolic demand 
of rapidly proliferating tumor cells, and subsequently promotes EMT. Cells then gain invasive 
and migratory properties, and intravasate into blood vessels. Within the blood, CTC travel to 
distant organ sites and extravasate to form dormant foci. Cells can remain dormant or undergo 
MET to form metastatic microtumors. Most CTCs undergo apoptotic death and are 
phagocytosed by macrophages; however, the minority can proliferate within the vasculature to 
form CTM, and eventually metastasis. Reprinted from reference [20]. © 2007, with permission 
from Elsevier. 
1.1.1 Epithelial-Mesenchymal transition  
Epithelial-mesenchymal transition (EMT) is a process by which cells that bear epithelial 
characteristics transform into mesenchymal phenotype, and can be classified into three types 
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based on biological context: type I occurs during embryogenesis and organogenesis; type II 
during fibrosis, tissue regeneration, and wound healing; and type III during tumorigenesis [21]. 
  EMT results in a spectrum of cells exhibiting partial to full mesenchymal phenotypes 
and stem cell properties. This is a complex process that involves cross-talk between several 
molecular pathways [22]. The increased expression of HIF within the tumor results in 
upregulation of TGF-β and integrins, as well as transcriptional mediators with known roles in 
mediating EMT, such as TWIST, SNAIL, and ZEB. These factors repress epithelial genes and 
activate mesenchymal genes leading to a loss of apicobasal polarity and spindle shape 
morphology and increases in cell motility and invasiveness (Table I-I).  
Cancer stem cells are cancer cells that have acquired characteristics of normal stem cells, 
including self-renewal and differentiation. They are responsible for tumor heterogeneity and the 
formation of metastatic foci [23]. They have been identified in multiple solid and hematological 
malignancies by the expression of population-specific markers, and account for tumor drug 
resistance and progression [24]. 
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Table I-I. Comparison between epithelial and mesenchymal phenotype. 
 Epithelial cells  Mesenchymal cells  
Cell shape  Apical-basolateral polarization Spindle  
Cell-Surface Proteins E-Cadherin  
ZO-1 
Claudins 
Mucin 1 
Desmoplakin 
N-Cadherin 
Downregulation / Attenuation  
   E-Cadherin  
   ZO-1(TJP) 
   Integrin 
Cytoskeletal Markers  CK 8 ,9 and 19 Vimentin  
β-Catenin 
FSP1 
Downregulation / Attenuation  
   Cytokeratin  
Growth pattern  Remain within epithelial layer 
and closely adjoined  
Form organized cell layer 
Presence of basal lamina 
Can migrate, highly motile & 
loosely adjoined  
Don’t form organized cell layer  
Focally present  
Transcription Factors  SNAIL 1 
SNAIL 2 
TWIST  
ZEB-1 
SMAD 
SIP1 
[21, 25] 
 
1.1.2 Metastatic inefficiency  
It is important to note that the presence of CTCs does not imply the development of metastasis. 
Evidence from animal models has demonstrated that only a subset of tumor cells, of the millions 
injected, survive to successfully graft and form tumors [26]. For instance, a study using murine 
melanoma cells tagged with a fluorescent marker demonstrated that 87.3% of cells remained 
within the vasculature at 90 minutes post-injection into the superior mesenteric vein of mice. By 
day three, 82% had extravasated into tissue, and 63% were lost by day 13. The majority of 
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extravasated cells remained as dormant, solitary cancer cells, with only 0.07% and 0.01% of 
injected cells forming micrometastases and macroscopic tumors, respectively [27]. Notably, 
most CTCs either undergo anoikis (programmed cell death as result of cell detachment from the 
extracellular matrix), immunogenic cell death, or apoptosis after extravasation and formation of 
dormant micrometastatic foci [27-30]. 
 
1.2 CTC Detection 
CTCs are often detected by isolating the exceedingly small CTC population from billions of 
RBC and millions of WBC within the blood through a process termed enrichment. There are 
many methods used to enrich and identify CTCs. The following section will discuss the 
techniques currently available and their advantages and disadvantages.  
1.2.1 Density gradient separation of mononucleated cells  
Density gradient separation is a classical method to separate cells based on their buoyant density 
[31]. Ficoll-Paque-Hypaque (GE Healthcare) is the most used separation reagent (Figure I-2). 
Blood is layered over the Ficoll-Paque in a conical tube and then centrifuged to form layers. 
Cells are arranged from bottom to top as red blood cells, granulocytes, density gradient, 
peripheral blood mononuclear cells (PBMCs), and plasma, where CTCs co-separate with the 
PBMC population. Collection of the PBMC must be performed immediately, otherwise cells 
begin to mix. This enriched population is then subjected to immuno-labeling, cytological 
analysis or molecular analysis in order to detect CTCs. 
OncoQuick is a modified density-based method that uses a porous barrier to prevent the 
PBMC from mixing with granulocytes and RBC after centrifugation. In direct comparison, both 
found to have similar performance in CTC recovery, although OncoQuick provides a slightly 
higher purity of PBMCs that facilitates immunocytological analysis and limits false positives in 
real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) screening. 
However, the increased purity comes at the expense of recovery, as OncoQuick has a recovery 
rate ranging between 70-90% due to the loss of normal and tumor cells to other phases [32]. 
Another alternative is RosetteSep™, which uses tetrameric antibody against 
glycoprotein A opposite of various leukocyte-specific antibodies, depending on your population 
of interest. The RosetteSep reagent is added to the isolated blood product. This results in the 
crosslinking of unwanted cells to RBC, forming rosette-like aggregates with high density, which 
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can then be pelleted with centrifugation. Importantly, this method has been found to minimize 
variability between operators and facilitate the processing of larger blood volumes [33]. 
 
 
Figure I.2. Ficoll density separation of PBMC and tumor cells. Blood is layered on top of 
Ficoll density gradient and is followed by centrifugation. Cells are arranged from the bottom to 
the top based on their buoyant density: RBC, granulocytes, PBMC and tumor cells, and plasma. 
The PBMC interphase can then be collected and used to detect and/or characterize tumor cells 
by cytological examination, immuno-labeling, or molecular analysis. Reprinted from reference 
[34]. © 2014, with permission from Nature Publishing Group. 
1.2.2 Size-based approach to CTC enrichment 
Average CTCs are reported to be larger than normal blood cells with an average size of 20-25 
µm compared to ~8 µm for normal leukocytes [35]. The isolation by size of epithelial tumor 
cells method, or ISET, uses a polycarbonate membrane with 8 µm pores. Whole blood is diluted 
with a buffer to fix cells, which are then filtered through the membrane. Cells larger than 8 µm 
trapped by the membrane are harvested, and then subjected to immunostaining and molecular 
analysis to detect and characterize the CTC population. This method has a reported detection 
sensitivity of one cell per mL of blood [36]. The main advantages of ISET include the 
enrichment of cells with intact morphology, as well as simplicity and reproducibility. However, 
its recovery rate ranges between 50-60% and tumor cells less than 8 µm are lost in the filtering 
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process [35], In addition, the membrane is fabricated by track etching to randomly distribute the 
pores, which might result fuse to create larger pores, and the clogging of pores can occur. 
Although, optimized filter construction with microfabrication has led to the production 
of membrane pores with precise size, geometry, and density in order to overcome the major 
limitations associated with track etching, and has improved the recovery rate to 90% (Figure I-
3) [37]. More recently, a 3D microfilter device has shown the ability to detect viable CTCs with 
a 90% capture efficiency from whole blood in 10 minutes [38]. 
 
   
Figure I.3. Comparison of microfabrication and track-etched membranes. Scanning electron 
microscopy (SEM) imagining demonstrating (A) microfabrication with precise size and 
geometry compared to (B) track etching that can result in randomly placed and/or fused pores. 
(C) SEM showing captured cells on microfabricated membrane. Reprinted from reference [37], 
© 2007 with permission from Elsevier.  
(A) (B) 
(C) 
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1.2.3 Magnetic immunolabeling isolation 
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that mediates 
homotypic cell-cell adhesions on epithelial cells [39]. Antibodies targeting EpCAM have been 
used to isolate CTCs directly through a process called positive enrichment. In contrast, negative 
enrichment is used to deplete leukocytes from a heterogeneous population with antibodies 
targeting CD45, a cell surface antigen expressed by both leukocytes and lymphocytes. 
The CellSearch® system (Veridex) is the only system approved by the FDA for the 
detection of CTCs, and uses ferrofluid nanoparticles conjugated to anti-EpCAM antibodies to 
magnetically isolate epithelial cells. Enriched cells are then stained with DAPI (4′,6-diamidino-
2-phenylindole) and for CD45 and/or cytokeratin 8, 18, or 19, and then analyzed with a 
CellTracks Analyzer. Cells positive for DAPI and cytokeratin, but negative for CD45, are 
considered CTCs. The system is semi-automated, fast, and has a detection sensitivity of 1 
CTC/mL. This method is capable of detecting CTCs in 36% of tested patients, with 85% 
recovery and 0.1% purity [35, 40], however, it is subject to false positives as result of non-
specific binding to Fc-receptor bearing cells, extraneous expression of epithelial antigens, 
inability to analyze cells, and false negatives for cancers that lack epithelial antigen expression 
due to EMT [35, 41-46]. Cells that are CD45 and CK positive are excluded from analysis and 
their prognostic value has not yet been evaluated; although, these cells can represent cancer stem 
cells or CTCs phagocytosed by leukocytes [47].  
The AdnaTest is another platform to positively enrich CTCs using multiple markers 
immunomagnetically. RNA is then isolated from the enriched cells and used for a multiplex 
qRT-PCR to detect CTC based on the expression of tumor genes. AdnaTest has a sensitivity of 
0.4 CTCs/mL of blood [48, 49].  
Negative enrichment can be used to detect CTCs regardless of their surface antigen 
expression. Yang et al. recently evaluated multiple products to negatively enrich CTCs and 
found that an anti-CD45 tetrameric antibody complex manufactured by StemCell® provided 
better enrichment than other products with average detection of 2.32 CTCs/mL of blood [50]. 
The variation in performance between different reagents can be explained by antibody binding 
capacity, as well as the size and composition of the magnetic particle [51]. Magnetic particles 
are bound to the antibody directly or indirectly through a secondary antibody. Indirect labeling 
by two-step binding was found to be more efficient and yields a higher affinity to cells [52]. The 
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loss of tumor cells due to leukocyte binding and their rarity within high background of 
leukocytes precludes the isolation of pure CTCs are disadvantages of negative enrichment-based 
analyses [53]. 
 
1.2.4 Microfludic systems for CTC isolation 
Microfluidics is a system used to manipulate and process micro-volumetric fluids using 
microchannels. The advantages of microfluidic cell isolation include its high throughput, 
sensitivity, and resolution that facilitate CTC detection and separation at a low-cost with high 
efficiency. This process also provides for gene expression analysis at single cell level and 
integration with other technologies [54]. These features make it ideal for the detection and 
enrichment of CTCs with minimal cell loss. As such, multiple microfluidics-based platforms 
have been developed to isolate CTCs based on both physical and immunological characteristics. 
 
1.2.4.1 Immunoaffinity based enrichment 
Nagrath et al. developed a CTC-chip microfluidic device consisting of an array of 78,000 
microposts coated with anti-EpCAM antibody embedded on silicon chip to capture CTCs [55]. 
Whole blood is passed through the chip at flow rate of 1-2 mL/h. CTCs were detected in 99% 
of cancer patients tested with an average purity of 55%, 80% recovery rate, and high 
experimental reproducibility. Enriched cells are 99% viable (Figure I-4) [55]. The same group 
reported on the detection and identification of CTCs with epidermal growth factor receptor 
(EGFR) genetic mutations in non-small-cell lung cancer using the Scorpion Amplification 
Refractory Mutation System (SARMS) technology designed to detect mutations involved in 
drug susceptibility or resistance. The CTC-chip detected CTCs in all tested patients with a 
median of 74 cells/mL of blood. Furthermore, EGFR mutations were identified from enriched 
CTCs in 95% of patients compared to 39% of patients from plasma examination [56]. The 
efficiency of the CTC-chip to enrich CTC is hindered with increasing the flow rate and shear 
force, and thus relies on laminar flow that reduce surface area of interaction.  
Stott et al. developed the Herringbone (HB)-Chip that consists of a glass slide bonded to 
a polydimethylsiloxane (PDMS) structure, containing eight microchannels with patterned 
herringbones on their upper surface with their internal walls coated with anti-EpCAM antibody 
[57]. The herringbone structure generates passive microvortices that disrupt the laminar flow 
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streamlines that carries the cells to increase the number of cell-surface interactions (Figure I-5). 
This improves the capture efficiency by 40%, which can be maintained at flow rates up to 4.8 
mL/h, compared to the 1-2 mL/h for CTC-chips.  
Dickson et al. developed the Cell Enrichment and Extraction™ (CEE) channel composed 
of 9000 randomly sized and positioned posts that are derivatized with streptavidin. Enriched 
cells are labeled with biotin-conjugated antibodies, which can then interact with streptavidin to 
capture CTCs. This allows for multiple surface markers to be targeted simultaneously with 
biotinylated antibodies to increase capture efficiency [58]. The capture efficiency of CEE is 
dependent on both antigen density and flow rate, and processing 8 to 10 mL of whole blood 
requires 7 to 9 hours.  
Gleghorn et al. developed the geometrically enhanced differential immunocapture 
(GEDI) chip optimized to maximize interactions with large cells (15 to 25 µm) and reduce wall 
shear force to enhance the capture of CTCs in prostate cancer cells using prostate-specific 
membrane antigen-antibody [59]. This optimization resulted in a 40% increase in efficiency and 
CTC capture from whole blood.  
Myung et al. further demonstrated the ability to capture CTCs through a functionalized 
epoxy glass immobilized with E-selectin and EpCAM antibodies [60]. 
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Figure I.4. CTC-chip. (A) Whole blood is passed through the chip using pressure regulated 
pump in laminar flow fashion. CTCs are captured against posts coated with anti-EpCAM 
antibody and can then be enumerated and characterized. Reprinted [61], © 2009 with permission 
from Wolters Kluwer Health . (B) SEM image demonstrating captured CTCs from a lung cancer 
patient. Reprinted from reference [55]. © 2007, with permission from Nature Publishing Group.  
 
Figure I.5. HB-chip. (A-B) Microvorticies generated by the HB-chip that increases cell-surface 
interactions compared to the CTC-chip (C-D) with laminar flow streamlines. Reprinted from 
reference [57]. © 2010, with permission from the National Academy of Sciences of the United 
States of America. 
(B) (A) 
(A) (B) 
(C) (D) 
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1.2.4.2 Immunomagnetic affinity  
Kang et al. developed an integrated micromagnetic-microfluidic device to capture and culture 
CTCs from animal cancer models [62]. CTCs captured with Anti-EpCAM microbeads are 
directed toward a culture plate after enrichment with RBC lysis buffer. This method has 87% 
capture efficiency and enriched CTCs are >90% viable (Figure I-6).  
Hoshino et al. later reported on a micromagnetic chip that captured CTCs with anti-
EpCAM-conjugated ferrous nanoparticles from whole blood with average capture rate of 86% 
at 10 mL/h flow rate and sensitivity of 5 CTCs/mL of blood (Figure I-7) [63].  
Chen et al. also described a negative enrichment of blood spiked with Jurkat T-cells into 
mononucleated cells (MNC) using a multistage magnetic-microfluidic disk [64]. Labeled cells 
are trapped and target cells collected in reservoir with successive increases in rotational speed. 
The average recovery of the device is 60%.  
 
Figure I.6. Schematic presentation of the integrated micomagnetic-microfluidic device. The 
devise is composed of a main channel and double collection channel lined by rows of dead-end 
side chambers. Magnetically labeled cells are collected when magnetic field is applied. 
Reproduced from reference [62]. © 2012, with permission from the Royal Society of Chemistry. 
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Figure I.7. Microchip design for immunomagnetic detection of cancer cells. Whole blood is 
admixed with anti-EpCAM antibody functionalized Fe3O4 nanoparticles to label CTCs. The 
blood then withdrawn using a regulated syringe pump through the chip where magnetic field 
collects labeled cells. Reproduced from reference [63]. © 2011, with permission from the Royal 
Society of Chemistry. 
1.2.4.3 Sized based  
Kuo et al. reported on a microchip optimized to detect spiked cancer cells based on size and 
deformability. The chip consists of a serpentine channel lined with rectangular apertures. This 
device captures CTCs with 90% or 50% recovery for fixed and unfixed cells from whole blood, 
respectively [65].  
 
1.2.5 Flow cytometry 
Advances in flow cytometry have allowed for the analysis of thousands of particles in a short 
amount of time and is currently used for cell sorting, counting, and biomarker detection. 
Fluorescence-activating cell sorting (FACS) separates cells based on their fluorescence 
following immunofluorescent labeling. Multi-parameter immunofluorescent labeling has 
demonstrated the ability to detect CTC [66], with Hu et al. reporting a sensitivity of one CTC 
for every 100,000 normal cells [67]. However, this platform lacks the sensitivity to isolate 
exceedingly rare cells, lengthy protocols to remove red blood cells and to stain the enriched 
population, as well as the high cost of the equipment [68].  
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Fiber-optic array scanning technology (FAST) combined with laser-printing optics can 
be used to excite 300,000 cells/second to achieve higher detection and sensitivity, and enables 
the processing of 100 million cells in 5 minutes [69]. Fixed cells are immunolabeled against cell 
surface markers and then read and analyzed with software to differentiate CTCs. However, this 
method lacks the capability to verify true positive cells. The author later improved the system 
by scanning isolated cells with automated digital microscopy (ADM). Despite these 
improvements, FAST/ADM only provides for the identification of viable CTCs, and not their 
enrichment, making it less conducive for clinical use necessitating the further characterization 
of CTCs [19].  
Epithelial immuonSPOT (EPISPOT) is a technique to detect viable CTCs based on 
protein secretion. Negatively enriched cells are cultured for one to two days on plates coated 
with antibody-specific protein markers on a nitrocellulose membrane. Cells are then washed off 
and a secondary fluorochrome-tagged antibody is used to detect the captured protein [70]. CTCs 
are identified based on the immunospots. This technique allows for multiple markers to be 
evaluated simultaneously and provides for CTC quantification. It has also been used to detect 
CTCs in breast cancer patients [71, 72]. However, the process is lengthy and the protein markers 
must be actively secreted by the tumor in order for detection [70].  
1.2.6 Dielectrophoresis 
Dielectrophoresis (DEP) technology enables the detection of unlabeled cells based on their 
dielectric properties. As the cells are exposed to a non-uniform electrical field, they differentially 
migrate toward the electric-field maximum based on their membrane properties, size, 
morphology, density, metabolic activity [73].  
Multiple DEP devices have been developed and optimized for the detection of CTCs 
[74]. Early technologies demonstrated a high recovery rate, purity, and viability [75-77], but 
was limited by its low throughput. Later, Gascoyne et al. developed dielectrophoretic field-flow 
fractionation (depFFF) to overcome these limitations, enabling the processing of up to 4.5 mL 
of blood with decreased time. [78]. However, the recovery efficiency ranged from 10-90% and 
was inversely related to PBMC concentration and chamber volume loading. Moreover, cell 
viability was dependent on immersion time, and most of the fractions collected first were non-
viable; and could be the result of low voltage tolerance. 
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An integrated microfluidic-DEP device using multi-orifice flow fractionation (MOFF) 
and dielectrophoresis (DEP) was also developed by Moon et al [79]. MOFF is first used to enrich 
cancer cells based on size by hydrodynamic inertial force, and are then further sorted by DEP. 
The system enables continuous flow-through separation in contrast to other platforms based on 
non-continuous batch separation. The MOFF/DEP method has 78.81% recovery rate with high 
purity.  
Gupta et al. introduced the ApoStream™ device comprised an integrated microfluidic 
flow chamber-modified depFFF that isolates cells based on the crossover frequency in 
continuous flow mode (Fig. I-8) [80]. DEP exerts a force on levitating blood cells, leading to a 
transition from negative to positive force to pull cancer cells toward the chamber floor while 
other blood cells are repelled and exit the chamber. The device can process 1.2 × 107 
PBMCs/hour with an average recovery of 74.9%, high purity, and leaves 97.6% of the cells 
viable.  
The major limitations of DEP in CTC enrichment are that whole blood cannot be 
processed, buffers must be optimized, purity issues resulting from some shared characteristics 
of CTCs and PBMC, and cells must be processed immediately to prevent early apoptotic 
changes that affect their dielectric properties [81, 82]. 
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Figure I.8. Schematic diagram of the ApoStream device. Levitating PBMC are exposed to DEP 
at a crossover frequency that separates PBMCs into waste chamber and CTCs into collection 
chamber. This crossover frequency ranges between 30-40 kHz for CTCs compared to 90-140 
kHz for PBMCs. Reprinted from reference [80], © 2012, with permission from AIP Publishing 
LLC. 
1.3 Detection and clinical applications in selected cancers  
1.3.1 Breast 
A prospective multi-center study reported that metastatic breast cancer patients with a detection 
of  ≥0.67 CTCs/mL of blood using the CellSearch system had lower progression-free and overall 
survivals [83, 84]. Using the AdnaTest to detect and genetically profile CTCs, Tewes et al. was 
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able to predict treatment responses in 78% of cases [85]. Furthermore, the persistence of CTCs 
after treatment is associated with poor prognosis [14]. 
Multiple ongoing interventional trials evaluating the utility of CTCs in treatment 
selection [86]. STIC CTC METABREAST (NCT01710605) is designed to assess progression 
free survival and medico-economics in metastatic hormone-dependent breast cancer based on 
the baseline of CTCs count before treatment initiation. Following randomization, the CTC-
driven decision cohort is treated with either hormonal therapy or chemotherapy based on cutoff 
of 5 CTCs/7.5 mL and compared to clinician choice cohort. In phase III trial, the SWOG 0500 
(NCT00382018) randomizes metastatic breast cancer patients with persistent elevated CTCs at 
the first follow-up assessment to changing therapy versus maintaining therapy. The overall 
survival, progression-free survival and toxicity are the primary outcome measures of this trial. 
In innovative approach, The DETECT III study (EudraCT 2010-024238-46) is randomizing 
HER2-negative metastatic breast cancer to standard therapy versus standard therapy combined 
with anti-HER2 targeted therapy based on HER-2 status of detectable CTC to assess 
progression-free survival.  
1.3.2 Colon  
CTC persistence at 4 weeks post-surgical intervention in patients with stage II-III colorectal 
cancer is associated with earlier cancer recurrence, as determined by membrane-array and qRT-
PCR analysis [87]. In a multi-institutional study, the qRT-PCR of multiple markers 
(CK/CEA/CD133) were used to detect CTCs in Dukes’ stage B and C found that CTC positivity 
was associated with lower disease-free and overall survival [88]. 
1.3.3 Lung 
CTCs identified in NSCLC decreased in quantity with treatment when measured with the CTC-
chip [55]. Maheswaran et al. described the detection of EGFR mutations in CTCs, which 
subsequently predicted drug response to EGFR tyrosine kinase inhibitor [56]. More 
interestingly, EGFR mutations were detected in 94% of patients with CTC analysis, compared 
to 34% by plasma testing. 
1.3.4 Prostate  
CTCs identified in 93% of castration-resistant prostate cancer patients with the CellSearch® 
system [89]. Baseline CTCs count more than 5 CTCs/7.5mL of blood was associated with poor 
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survival.  Moreover, CTCs serial follow during treatment in castration-resistant prostate cancer 
served as surrogate marker to predict response to treatment and survival [90, 91]. In a 
randomized, double-blind, placebo-controlled, phase III trial assessing abiraterone acetate 
following docetaxel, CTCs enumeration was evaluated prospectively as surrogate efficacy 
response biomarker of overall survival in metastatic castration-resistant prostate cancer [92]. 
CTC conversion from unfavorable counts, defined as CTC ≥ 5/7.5 mL of blood, to favorable 
counts was predictive of overall survival.  
CTCs have been detected in ovarian, hepatocellular carcinoma, bladder transitional 
carcinoma and many other types [93-95]. The field of CTCs detection and their clinical 
applications are evolving rapidly and provide insights into personalized medicine approach [96]. 
Isolating CTCs and successfully culturing them in ex-vivo enabled genomic profiling and 
assessing molecular pathways involved in tumorigenesis to predict sensitivity of targeted cancer 
therapy [97, 98]. In HER-2 negative breast cancer, 40% of patients with detectable CTC had 
HER-2 expression [99]. This finding has led to the initiation of The DETECT III study 
(EudraCT 2010-024238-46) that’s primary objective to evaluate treatment response targeting 
anti-HER-2 based on molecular characterization of detectable CTCs. 
In summary, CTCs detection and characterization have a wide range of clinical 
applications; predict disease prognosis; evaluate response to treatment; genomic profiling; 
predict drug sensitivity and selection of patients for adjuvant systemic/targeted treatments. 
 
1.4 Human papillomavirus  
HPV is a non-enveloped, circular double-stranded DNA, epitheliotropic virus (Figure I-9). It 
belongs to the Papillomaviridae family and more than 100 types have been reported [100, 101]. 
HPV are classified into high and low risk types based on their oncogenic characteristics [102-
104]. 
The genome is organized into the early, late, and long control regions (LCR) (Figure 1-
10). The LCR has no protein coding function. The early region contains E1, E2, E4, E5, E6, E7 
and E8 open reading frames (ORF). The late region encodes L1 and L2 capsid proteins [105-
107]. The L1 ORF has the most conserved DNA sequence of the HPV genome, because of that 
it is widely used for viral typing. Differences of >10%, between 2% and 10%, and <2% 
constitutes new papillomaviruses isolates, subtypes, and variants respectively [101]. 
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E6 and E7 oncogenes encode for the oncoproteins with the same name, E6 and E7 [108-
110]. Together, the E6 and E7 expression are necessary and sufficient to induce cellular 
transformation and immortalization [111, 112]. Importantly, the oncoprotein E6 can bind p53 
resulting in the p53 ubiquitin-mediated degradation, and can also induce BAK (Bcl-2-
homologous antagonist/killer) degradation and telomerase activation. The oncoprotein E7 binds 
and inactivates retinoblastoma tumor suppressor (Rb) that leads to the release of the E2F 
transcriptional activator, which inhibits cyclin-dependent kinases (CDK) and indirectly induces 
p16INK4A.  
During the progression of oncogenic HPV-infected lesion, the viral genome integrates 
into to the host genome [113]. The net effect is induction of genomic instability, cellular 
immortalization, and malignant transformation (Figure I-11) [109, 110, 114-117]. Abolishing 
E6 and E7 expression in cervical cancer cell lines leads to growth arrest, cellular senescence, 
and apoptosis [118-123].  
 
Figure I.9. HPV life cycle. HPV infection is confined to epithelial cells. Following access to 
the basal cell layer, the viral promoter induces E6 and E7 expression to initiate S-phase entry, 
viral genome amplification, and protein expression during epithelial cell differentiation. Viral 
capsid proteins are formed at the uppermost layer leading to viral particle assembly and release. 
The viral genome is maintained at low copy number at the basal layers by the E1, E2, E6 and 
E7 proteins. E4 and E5 are necessary to aid E6 and E7 expression. Reprinted from reference 
[124]. © 2005, with permission from Elsevier. 
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Figure I.10. The HPV genome and ORF function. E1 and E2: viral DNA replication. E4: viral 
release and packaging. E5: immune evasion, proliferation, and enhances E6 and E7. E6 and E7: 
oncoproteins. L1: major capsid protein. L2: minor capsid protein. The Upstream Regulatory 
Region (URR) that harbors the viral promoter and enhancer. Reprinted from Reference [125]. 
© 2012, with permission from the American society for Microbiology. 
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Figure I.11. E6 and E7 molecular mechanisms of inducing malignant transformation. E6 
forms a complex with E6AP that functions as p53-specifc ubiquitin-protein ligase, leading to its 
degradation and the subsequent inhibition of the CDK inhibitor p21. The sequestration and/or 
degradation of p53 leads to cell cycle deregulation, DNA damage repair, and cellular 
senescence. The E6/E6AP complex additionally degrades NFX1, a transcriptional repressor of 
hTERT, resulting in cellular immortalization. E7 induces Rb degradation leading to liberation 
of the E2F-1 transcriptional factor. Furthermore, the p16 CDK inhibitor, which inhibits Rb 
phosphorylation, is indirectly induced through activation of E2F-1. E7 rescues the functional 
activity of E6 by inhibiting p21 and p27 CDK inhibitors, leading to activation of cyclin A and 
E. The net effect is induction of genomic instability, cellular immortalization, and proliferation. 
Reprinted from reference [126]. © 2009, with permission from AACR. 
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1.5 Uterine cervical Cancer  
Uterine cervical cancer (UCC) is the fourth most common cancer affecting women worldwide, 
and the fourth leading cause cancer related deaths in women. There were 528,000 estimated new 
cases of UCC in 2012, with 85% occurring in developing countries [127].  
HPV is an etiological risk factor for the development of cervical cancer and HPV DNA 
is detected in 99.7% of cervical carcinomas [128]. HPV is the most common sexually 
transmitted disease with a 79% estimated lifetime risk of cervical infection [129, 130]. Two 
high-risk HPV types, HPV16 and 18, account for 73% of cervical cancer cases; whereas HPV31, 
33, 35, 39, 45, 51, 52, 56, 58, and 59 account for the remaining cases [131].  
The International Federation of Gynecology and Obstetrics staging system (FIGO 2009) 
used to stage cervical cancer relies on clinical and basic radiological assessment [132, 133]. In 
developed countries, surgical staging and advanced radiological techniques are used to guide 
treatment [134-136]. The treatment of early stage cancer usually consists of surgery or primary 
radiotherapy with comparable outcomes [137]. Despite primary surgical treatment, 
approximately 50% of patients require adjuvant radiotherapy following the identification of 
further risk factors at final surgicopathological examination. This combined treatment is 
associated with increased morbidity [137]. In addition, risk factors that are detrimental for 
prognosis include pelvic lymph node metastasis, parametrial involvement, and positive resected 
margins [138, 139].  
Pelvic lymph node metastasis is an independent prognostic factor associated with a 
decrease in disease-free and overall survival. Although the risk of nodal metastasis is about 21% 
in early stages [140], radiological assessment lacks the sensitivity to detect lymph node 
metastases [141]. The sensitivity of PET/CT scan, MRI, and CT to detect lymph node metastases 
is 75%, 56%, and 58%, respectively. Additionally, metastatic size <5 mm are below the 
detection limit of these technologies [142]. Approximately 15% of stage IB patients relapse, 
despite the absence of lymph node metastasis by routine histopathological examination and clear 
surgical margins [138]. Horn et al. retrospectively re-examined surgically resected pelvic lymph 
nodes and detected micrometastasis in 22.2% of patients and found a range between 3.8-23.9% 
in previously published literature [143]. In breast cancer, the reexamination of lymph nodes 
previously reported as negative with current methods of serial sectioning and 
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immunohistochemistry (IHC) detected occult metastasis in 20% of patients compared to 7% by 
haematoxylin and eosin (H&E), which correlated with poor prognosis [144].  
Micrometastases are defined as tumor cell clusters more than 0.2 mm to and including 2 
mm in size, whereas isolated tumor cells (ITC) are 0.2 mm or less. Using IHC and serial cuts, 
they are found in 10-90% of lymph nodes determined to be negative by routine histological 
examination [145, 146]. In cervical carcinoma, micrometastasis is an independent risk factor 
associated with reduced overall survival [147, 148]. Ultrastaging has improved the detection 
rate of lymph node metastasis [149, 150]; however, the technique is cumbersome and requires 
the examination of several histological slides.  
Sentinel lymph node (SLN) mapping has emerged to improve detection rates and reduce 
the complications associated with complete pelvic lymphadenectomy [150-152]. The SLN is the 
first lymph node in the lymphatic pathway draining from a tumor and, if that lymph node is 
negative, then all others are also assumed to be negative. However, the performance of SLN 
depends on multiple factors including the technique used to detect the SLN [147, 153], surgical 
experience [154], tumor volume [155, 156], and pathological examination [147, 157]. In a large 
multicenter retrospective study, SLN and ultra-staging was able to identify micrometastases at 
a sensitivity of 91% with a false negative rate of 2.8% [158]. 
 
1.6 CTCs in UCC 
Studies addressing CTC in UCC are scarce. Pao et al. used a Ficoll-Paque density gradient 
medium to enrich CTCs, which were then subjected to qRT-PCR analysis to detect HPV16 E6 
expression. Notably, the E6 transcript was detected in 92% of stage IV-B UCC [159]. In follow-
up publication by the same group, HPV16 and/or 18 E6 oncogenes expression was detected in 
51.4% of locally advanced UCC cases, and positivity was associated with higher recurrence 
risk, the presence of distant metastasis, and lower overall survival [160]. In addition, Weismann 
et al. was able to detect ≥25 spiked cells in 7.5 mL of blood after enrichment using Ficoll-Paque 
followed by a secondary positive enrichment with αEpCAM antibody; however, the average 
recovery was 50% and CTCs were undetectable if present at <25 cells/mL of blood. 
Nevertheless, the technique could detect CTCs in 23% of patients with early-state UCC [161]. 
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Digital-Direct-RT-PCR of HPV16/18 E6 expression demonstrated a sensitivity of 1 CTC 
for every 500,000 normal cells, and a sensitivity of 5 CTCs/mL of blood, which was inversely 
related to the background number of PBMCs [162].  
In contrast, nested RT-PCR for the cytokeratin-19 (CK19) transcript was sufficient to 
detect CTCs in 21.4% of stage IB-IIB patients; although, its expression did not correlate with 
any clinicopathological parameters [163].  
Finally, Mitsuhashi et al. comparatively assessed the use of EGFR and CK19 qRT-PCR 
for the detection of CTCs. Notably, EGFR was expressed in 98% of primary tumors and was 
detected in the blood of 26.7% cancer patients, with no detectable levels in normal controls; 
whereas, CK19 was detected in 77.8% and 65% of patients and normal controls, respectively 
[164].  
 
1.7 Hypothesis and Objective  
Tumor markers expressed by cancer cells that can be used to detect them and to monitor their 
progression [165]. These markers can be organ-specific, tumor-specific, or tumor non-specific. 
The ideal marker should be exclusively expressed in tumor cells and be organ-specific. For 
instance, prostate cancer expresses prostate-specific antigen (organ-specific). Alfa-fetoprotein 
is expressed by hepatocellular carcinoma and yolk sac tumor (tumor-specific). Cytokeratin are 
variably expressed in epithelial cells and the most prevalent in tumor cells of epithelial origin 
(tissue-specific and tumor non-specific). CA-125 a common tumor marker that is expressed by 
epithelial ovarian cancer is also expressed by other tumors such as the breast, lung and 
gastrointestinal (organ non-specific and tumor non-specific) [166]. However,  tumor markers 
are not entirely specific as they can be expressed in many benign conditions and by multiple 
tumors [165].  
The current method used to detect RNA expression in tumor cells and has a wide range 
of clinical applications is the qRT-PCR, which indirectly assess genes expression [167, 168]. 
The qRT-PCR sensitivity is one target cell per 10 million, corresponding to approximately to 
one cell per 0.1-1 mL of blood [26]. Multiple studies have reported on the detection of CTCs 
using cytokeratin, prostate-specific antigen, and other tumor-specific markers using qRT-PCR 
[169-172].  
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Cytokeratin are a family of intermediate filament proteins that participate in the 
formation of the cellular cytoskeleton. The two types of CK proteins, acidic type I and 
neutral/basic type II, both of which are variably expressed in epithelial cells and are usually 
maintained during malignant transformation [173]. CK8, CK18, and CK19 are the most 
prevalent in tumor cells of epithelial origin [174]. A previous study assessing the use of CK19 
qRT-PCR analysis for the detection of lymph node micrometastasis in cervical cancer found 
CK19 expression in ~50% of lymph nodes. Moreover, 44% of lymph nodes deemed negative 
by histological analysis were found positive for CK19 expression, a result that correlated with 
clinicopathological features [175]. In breast carcinomas, a one-step nucleic acid amplification 
assay (OSNA) for CK19 used for the rapid intraoperative detection of lymph node metastasis 
has a sensitivity of 93.3% [176]. In comparison, frozen section has 58% sensitivity for detecting 
nodal micrometastasis [177]. Similar findings have been reported for the analysis of frozen 
sections in cervical cancer with a sensitivity range of 20.7-56.2% [178-180]. This suggests that 
CK19 OSNAs may be of potential value in the management of UCC to avoid further 
unnecessary surgical procedures and quickly identify the proper standard of care. 
HPV DNA can be detected in 99.7% of UCCs [128]. The E6 and E7 oncoproteins 
encoded by HPV are constitutively expressed and facilitate the development and maintenance 
of a malignant phenotype. Thus, they are ideal molecular markers to detect CTCs in UCC 
patients [118-123]. Notably, a previous study identified CTCs in 92% of stage IV-B UCC 
patients by analyzing HPV16 E6 oncogene expression [159]. In follow up study, the HPV16 
and/or 18 E6 oncogenes expression were detected in 51.4% of locally advanced UCC cases, 
which was associated with a higher risk of recurrence, distant metastasis, and lower overall 
survival [160]. 
The cyclin dependent kinase (CDK) inhibitor p16INK4A functions as tumor suppressor 
and regulates the G1/S cell cycle transition by binding CDKs to inhibit the phosphorylation of 
Rb. This prevents the release of E2F transcription factors and aberrant transition into S-phase 
[181, 182]. p16INK4A is indirectly overexpressed in cervical cancer as result of the functional 
inactivation of Rb by E7 and can be used as biomarker for diagnosis [183]. 
Despite the numerous studies addressing CTCs in many other cancers, only a limited 
amount of information is available for the use of CTCs in UCC diagnostics. Due to their known 
roles in UCC etiology and lack of expression in normal cells, we hypothesize that HPV 
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oncogene expression will allow for the detection of CTCs and lymph node metastases with high 
sensitivity. These findings have the potential to improve current CTC detection methods for 
UCC and to determine the potential clinical impact of these cells in UCC management. Thus, 
we propose to use these markers to detect CTCs.  
Objective #1:  
Optimize, establish protocols and validate for the use of E6/E7, CK19 and p16INK4A 
genes expression to detect CTCs and lymph node metastases in UCC. 
Objective #2:  
Develop a tumor bank consisting of tumor tissue biopsies, plasma, and PBMCs 
accompanied with HPV DNA genotyping and clinical data for UCC patients treated at the 
Centre Hospitalier de l'Université de Montréal (CHUM).  
Objective #3:  
Determine the capacity of CK19, p16INK4A, E6, and E7 expression analysis by qRT-PCR 
to detect CTCs in patients with UCC. 
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CHAPTER II : MATERIALS AND METHODS 
2.1 Cell Culture 
The HeLa, HCA2-hTERT, U2OS, and AT3-OVA cell lines were cultured in Dulbecco's 
Modified Eagle Medium (DMEM). The CaSki cell line was cultured in RPMI media. TOV-
1946, TOV-112D, and TOV-21G were cultured in OSE medium (Table II-I). All culture media 
were supplemented with 8% Fetal Bovine Serum (FBS), 100 IU/mL penicillin, and 100 g/mL 
streptomycin, and grown at 37°C in a humidified atmosphere of 5% CO2. Cells were passaged 
every two to three days prior to confluency with 0.05% trypsin supplemented with 0.53 mM 
EDTA. 
Table II-I. Cell line 
Cell Line Origin 
HeLa Uterine cervical adenocarcinoma (HPV18 DNA-positive, about 
10-50 copies per cell). Obtained from the American Type Culture 
Collection (Manassas, VA). 
HCA2-hTERT Immortalized human fibroblast [184]. 
U2OS Human osteosarcoma [185].  
AT3-OVA Mice breast carcinoma [186]. 
CaSki Uterine cervical squamous cell carcinoma (HPV16/18 DNA 
positive, about 60-600 copies per cell). However, HPV16 RNA 
is solely expressed [187]. Obtained from the American Type 
Culture Collection (Manassas, VA). 
TOV-1946  High grade ovarian serous carcinoma [188].  
TOV-112D High grade endometroid ovarian carcinoma [189]. 
TOV-21G Clear cell ovarian carcinoma [189]. 
 
2.2 Ficoll-Paque Density gradient enrichment  
2.2.1 Validation  
A solution containing 15 mL of each FBS and PBS was prepared and spiked with a pre-
determined number of cells. It was then layered over 15 mL Ficoll-Paque in a 50 mL conical 
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tube. After centrifugation at 400g at 20°C for 30 minutes without breaking, the cell layer above 
the Ficoll-Paque was collected and transferred to a separate tube. In addition, the cell-free phases 
above the cell layer and below the Ficoll-Paque were collected and transferred into new tubes. 
Cells were washed twice with PBS and counted with a hemocytometer and TC20™ automated 
cell counter. 
2.2.2 Enrichment of spiked cancer cells  
Blood from healthy volunteers were collected in EDTA tubes. HPV16-positive CaSki-GFP cells 
were serially diluted and spiked into blood. The spiked blood was further diluted 2-4-fold with 
cold PBS containing 2 mM EDTA. After centrifugation at 400g at 20°C for 30 minutes without 
breaking, the following layer phases were formed from the bottom to the top: erythrocyte, 
granulocytes, Ficoll-Paque, PBMC, and plasma. The PBMC layer was collected and transferred 
to a separate tube and washed twice with cold PBS, and equally divided for RNA extraction and 
formalin fixation for flow cytometry. 
2.3 Enrichment by RBC lysis 
CaSki-GFP cells was serially diluted and spiked into blood collected from healthy donors. CTCs 
were then enriched by adding 10 mL of ACK RBC lysis buffer per mL of blood and incubating 
for 5 minutes at room temperature kept in gentle agitation. Incubations were extended for an 
additional 5 minutes if the RBC lysis was not complete [113]. Cells then were collected by 
centrifugation at 400g at 4°C for 5 minutes, washed once with cold PBS, and then split equally 
for RNA extraction and formalin fixation for flow cytometry. 
2.4 Flow cytometry strategy for sorting and counting CTCs 
GFP-tagged CaSki cells were used to differentiate target cells from normal PBMCs. Following 
enrichment, cells were fixed with 1% cold formalin for 10 minutes at 4°C and washed once with 
cold PBS. Fixed cells were preserved in 75% ethanol at −20°C. CountBright™ Absolute 
Counting Beads were used to determine the absolute number of recovered cells. Briefly, 
previously enriched fixed cells were washed once with PBS, resuspended in 1000 µL PBS, and 
50 µL bead slurry (50,000 Beads in 50 µL) was then added to each suspension. The following 
formula was used to calculate cell concentration:  
 
(Number of cell events/Number of bead events) × (Assigned bead count /Volume of sample) = 
Cells/µL 
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Where the number of cell and bead events represent cells and beads detected following 
excitation.   
Flow cytometry data was collected on a BD LSRFortessa™ cell analyzer and analyzed 
with FlowJo software (Figure II-1). Enriched cells were not stained with DAPI whereas the 
beads are positive when exited with the DAPI channel.  
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Figure II.1. Flow cytometry gating strategy to isolate GFP-positive spiked cancer cells. (A-C) 
Fluorescence intensity histogram with indicated gate setting. GFP intensity and counts are 
plotted on the x- and y-axes, respectively. (A) CaSki (red) vs CaSki-GFP (green) vs CaSki cells 
based on GFP fluorescence. (B) PBMC (red), CaSki-GFP (green), and counting beads (blue) 
based on GFP fluorescence. (C) PBMC (red), CaSki-GFP (green), and counting beads (blue) 
based on DAPI fluorescence. (D) Forward scatter versus side scatter plot (FSC vs. SSC) on total, 
ungated events demonstrating the three populations as indicated. (E) Total events on GFP 
CaSki CaSki-GFP 
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intensity histogram. (F) FSC vs. SSC on GFP-negative PBMCs (G) FSC vs. SSC on GFP-
positive gating for CaSki-GFP cells and counting beads. (H) GFP-positive gating based on 
DAPI intensity. (I) FSC vs. SSC on GFP-positive/DAPI-negative CaSki-GFP cells. (J) FSC vs. 
SSC plot on GFP-positive/DAPI-positive counting beads. Note: enriched cells were not stained 
with DAPI whereas the beads are positive when exited with the DAPI channel.   
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2.5 Real-time quantitative reverse-transcription polymerase chain reaction 
(qRT-PCR) 
2.5.1 Reverse transcription  
RNA was isolated by Trizol® extraction from the enriched cell pellet per the manufacturer’s 
instructions. The RNA concentration and purity was determined spectrophotometrically based 
on absorbance at 260 nm and 280 nm.  Equivalent amounts of RNA (≤1 μg) was reverse-
transcribed into cDNA with Superscript® III First-Strand Synthesis SuperMix in a 20 µL 
reaction volume. The reaction mix composed of 10 µL of 2xRT reaction mix, two µL of reverse 
transcriptase enzyme, RNA (maximum 8 µL) and water free RNase to complete the volume to 
20 µL. The mixture was then subjected to the following thermocyling protocol: 10 minutes at 
room temperature, 50°C for 30 minutes, and 85°C for 5 minutes, followed by chilling on ice. 
Hereafter 1 µL RNase H was added to the reaction mix and incubated at 37°C for 20 minutes. 
The cDNA was stored at -20°C until further analysis.  
2.5.2 Multiplex real-time PCR reactions  
Multiplex real-time PCR reactions for HPV16 E6 and E7, CK19, and p16INK4A were performed 
to detect CTCs. TaqMan® assays were used to assess E6, E7, CK19, and p16INK4A gene 
expression. 18S ribosomal RNA and/or TATA-box binding protein (TBP) were used as internal 
references. The Oligo Analyzer 3.1 and BLAST software (Basic Local Alignment Search Tool) 
were used to verify the specificity of primers and probes sequences listed in Table II-II. Primers 
and probes were purchased from Integrated DNA Technologies. Real time quantitative PCR 
reactions were performed using Platinum® Quantitative PCR SuperMix-UGD in a 15-µL 
reaction volume. Maximum 50 ng/µL of cDNA was used per reaction. The reaction mix 
composed of 3 µL of cDNA, 7.5 µL of master mix, 0.6 µL of MgCl2; to a final concentration of 
4.0 mM, 0.3 µL of probe; to a final concentration of 0.2 µM and 0.3 µL  of each primer; to a 
final concentration of 0.2 µM.  RNase free water was used to complete the volume to 15 µL.  
PCR reactions were run on a StepOnePlus™ Real time PCR instrument with initial incubations 
at 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds 
and 60°C for one minute. Reactions were performed in triplicates with positive, negative, and 
no template controls (NTC). Data was analyzed with StepOne™ Software by the comparative Ct 
method. 
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Table II-II. Sequence of primers and TaqMan probes. 
Genes Sequence (5’-3’) Location Product size (Bp) 
18s 
Forward 
Reverse  
Probe  
 
CGGCTACCACATCCAAGGAA 
CGCTATTGGAGCTGGAATTA 
TGCTGGCACCAGACTTGCCCTC 
450-646 197 
TBP 
Forward  
Reverse 
Probe  
 
ACAGGAGCCAAGAGTGAA 
AAACCCAACTTCTGTACAAC 
ACAGTCCAGACTGGCAGCAAGAAAATA 
743-816 
 
74 
 
HPV16 E7 
Forward 
Reverse  
Probe 
 
CAAGCAGAACCGGACAGA 
GTCTACGTGTGTGCTTTGTA 
CAAGTGTGACTCTACGCTTCGGTTGTG 
691-786 96 
HPV16 E6 
Forward 
Reverse  
Probe 
 
AATGTTTCAGGACCCACAGG 
CTCACGTCGCAGTAACTGTTG 
AGCGACCCAGAAAGTTACCACAGTTATG 
103-226 124 
CK-19 
Forward 
Reverse  
Probe 
 
TCGACAACGCCCGTCTG 
CCACGCTCATGCGCAG 
CCTGTTCCGTCTCAAACTTGGTTCGG 
606-680 75 
P16INK4A 
Forward 
Reverse  
Probe 
 
CTGCCCAACGCACCGAATA 
GCGCTGCCCATCATCATGA 
CTGGATCGGCCTCCGACCGTA 
415-476 62 
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Relative expression of the target gene  
The mean cycle threshold value (CT) was determined for the target gene (CT, target) and the 
endogenous control (CT, ec), which represents the PCR cycle number at which the fluorescent 
signal is first detectable. Relative expression (ΔCT) of the target gene was calculated by 
subtracting (CT, ec) from (CT, target). Relative fold expression was calculated by the following 
equation: 2-ΔCT. 
2.6 Uterine cervical cancer patients  
All patient experiments were performed with the approval of the CHUM institutional review 
board. Blood was collected from HPV16-positive UCC patients at diagnosis in EDTA tubes and 
processed within 6 hours. PBMCs were non-magnetically enriched using ACK RBC lysis buffer 
with the exception of two patients enriched by Ficoll centrifugation. RNA was stored in 
TRIzol® at -80°C until further analysis. Then, RNA was isolated by TRIzol® extraction from 
the enriched cell pellet per the manufacturer’s instructions. The RNA concentration and purity 
was determined spectrophotometrically based on absorbance at 260 nm and 280 nm. Multiplex 
qRT-PCR reactions for HPV16 E6 and E7, CK19, and p16INK4A were performed to detect CTCs. 
TBP was used as endogenous control. Normal PBMCs isolated from healthy females served as 
negative control.  
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CHAPTER III : RESULTS  
3.1 Validation of Ficoll-Paque Enrichment 
To optimize our enrichment procedures and define the source(s) of lost CTCs, we first wanted 
to determine the phases where CTCs localize. From our analysis, we found that an average of 
50% of CTCs are located immediately above the Ficoll-Paque layer, whereas the remaining cells 
distributed in either the uppermost or bottommost phases or were lost during washing process. 
Interestingly, cell lines derived from aggressive tumors exhibited a very low recovery 
rate (HeLa, U20S, and AT3-OVA) (Figure III-1).  
 
Figure III.1. Ficoll-Paque density gradient for cell separation. UCC cells localized in the layer 
immediately above the Ficoll-Paque phase. Recovery is plotted on the y-axes and varies greatly 
across cell lines with an average recovery of 50%. Values represent the mean ± standard error 
of the mean (SEM) for three independent experiments per cell line. 
3.2 E6 and E7 oncogenes expression after enrichment using Ficoll-Paque 
density gradients 
Figure III-2 demonstrates the detection of both markers from CaSki-GFP spiked at fixed 
concentrations in blood. We found that E7 detection was more sensitive than E6 from 
experiments performed in triplicate. Figure III-3 shows a lower detection limit of 103-104 
cells/mL in blood for both markers, as determined by experiments performed at least in 
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duplicate. Below that threshold, we failed to observe a downward trend in the CT value that 
corresponds to the spiking scheme. In addition, the detection of E6 and E7 was not consistently 
reproducible below 1000 spiked cells/mL of blood, indicating the low sensitivity of Ficoll-Paque 
enrichment. 
 
 
Figure III.2. Detection of HPV16 E6/E7 expression  from CaSki UCC cells spiked into human 
blood following Ficoll-Paque density gradient enrichment. Blood spiked with 260,000 CaSki 
UCC cells was subjected to Ficoll-Paque enrichment for CTCs. RNA extracted from the 
enriched cells was subjected to qRT-PCR analysis for HPV16 E6 and E7 expression. Pure CaSki 
or PBMCs were used as positive and negative controls, respectively. Relative expression 
normalized to 18s ribosomal RNA is plotted on the y-axis.  
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Figure III.3. HPV16 E6/E7 expression detection limits from CaSki cells spiked into human 
blood following Ficoll-Paque density gradient centrifugation. Blood samples were spiked with 
serial dilutions of CaSki cells and subjected to Ficoll-Paque enrichment. RNA extracted from 
the enriched cell pellet was analyzed for HPV16 E6/E7 expression by qRT-PCR. Relative 
expression normalized to 18s ribosomal RNA is plotted on the y-axis. 
3.3 Detection of spiked cancer cells using flow cytometry following Ficoll-
Paque enrichment 
Ficoll-Paque enrichment demonstrated low recovery percentage and inter-sample variation (1.7-
5.6%) (Table III-I), consistent with previous results from the qRT-PCR analysis. From this data, 
we concluded that the CTC detection threshold ranged between 1000-10,000 cells/mL of blood, 
below which we were unable to detect any cancer cells (Table III-II). 
Table III-I. Flow cytometry cell count following enrichment by Ficoll-Paque. 
Spiked cells per mL of blood Recovered Cell counts/mL of Blood Recovery % 
Negative control N/A N/A 
260,000 15144 5.6 
260,000 4543 1.7 
260,000 11246 4.2 
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Table III-II. Flow cytometry cell count following enrichment by Ficoll-Paque: Detection 
limit. 
Spiked cells per mL of blood Recovered Cell counts/mL of Blood Recovery % 
Negative control N/A N/A 
10,000/mL 456 4.5 
1000/mL ND ND 
500/mL ND ND 
100/mL ND ND 
50/mL ND ND 
3.4 Detection of spiked cancer cells by flow cytometry following RBC lysis 
enrichment 
Enrichment by RBC lysis demonstrated a much higher recovery percentage, varying between 
57-98.4 %, compared to Ficoll-Paque. Due to background activity, this single parameter method 
was reliable in isolating spiked cancer cells down to a threshold of 5,000 cancer cells/mL of 
blood (Table III-III). Below that threshold, the background activity is consistently higher than 
the number of spiked cells which account for higher percentage recovery (>100%). 
Table III-III. Flow cytometry cell count following enrichment by RBC lysis  
Spiked cells per mL of Blood Recovered Cell counts/mL of Blood Recovery % 
Negative control N/A N/A 
80000 51,100 63.9 
40000 34300 85.8 
20000 11800 59.0 
10000 5712 57.1 
5000 4920 98.4 
2500 9030 361.2 
1000 2392 239.2 
500 1680 336.0 
250 4740 1896.0 
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CHAPTER IV : ARTICLE  
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Running title: Detection of rare uterine cervical cancer cells using molecular 
biomarkers 
RÉSUMÉ 
Arrière-plan: 
Le cancer du col de l'utérus (UCC) est le quatrième cancer de la femme en incidence dans le 
monde entier. L’essaimage des cellules cancéreuses (métastases) a un impact direct sur notre 
capacité à guérir le cancer.  Pour le patientes atteintes de UCC, la présence de métastases 
ganglionnaires est un important facteur de risque indépendant associé à un mauvais pronostic. 
La détection de cellules tumorales circulantes (CTC) a également une valeur pronostique dans 
de nombreux cancers (sein, poumon, du côlon et de la prostate), mais cela n'est pas encore utilisé 
pour les UCC. Actuellement, le traitement du UCC est guidé par l’évaluation clinique et 
histologique. L'avancement dans les techniques moléculaires pour la détection de cellules 
cancéreuses disséminées rares pourrait améliorer considérablement la gestion de la maladie. 
 
Objectif: 
Utiliser des biomarqueurs moléculaires pour optimiser le processus d’enrichissement et de 
detection des cellules tumorales dans la circulation sanguine et les ganglions lymphatiques chez 
les patientes atteintes de UCC.  
 
Matériel & Méthodes: 
Nous avons lysé en Trizol une série de dilutions séquentielles d’une population mixte de cellules 
HeLa/CaSki et CaSki/HCA2-hTERT à l’aide de cellules fraîches et de cellules fixées à la 
formaline enrobées dans la paraffine, imitant les ganglions lymphatiques. Des cellules CaSki 
ont été ajoutées à des échantillons sanguins d’individus sains et nous avons comparé 
l’enrichissement positif ou négatif et l’absence d’enrichissement pour la collecte des cellules 
CaSki lors de la lyse des globules rouges. Les cellules cancéreuses ont été détectées par qRT-
PCR sur les E6, E7, CK19 et p16INK4a. 
 
Résultat:  
La limite de détection pour les E6 et E7 des VPH 16/18 est de 0.008% (1:12500 cellules) sur les 
échantillons frais et de 0.02% et 0.05% pour les HPV16 E6/E7 et HPV18 E6/E7 pour les 
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échantillons fixées en bloc de paraffine. La lyse des globules rouges seule ou couplée avec de 
l’enrichissement positif ou negative a une limite de detection de 50 cellules par mL de sang pour 
E6, E7, Ck19 et p16INK4a. La sensibilité de la qPCR augmente avec l’enrichissement en réduisant 
le bruit de fond causé par les monocytes sanguins. Le gène p16INK4a est exprimé dans les 
individus normaux et peut être utilisé si la valeur d’expression médiane est déterminée. 
 
Conclusion: 
L’analyse par qRT-PCR des oncogènes du VPH est plus sensible pour détecter un ganglion 
lymphatique micrométastatique que l’examinen histologique. La détection par qRT-PCR des 
oncogènes du VPH, de CK19 et de p16INK4a dans les échantillons sanguins qRT-PCR montre 
une grande sensibilité.  
 
Mots clés: diagnostic, carcinome cervical utérin, d'évaluation pré-thérapeutique, oncogènes 
viraux, des ganglions lymphatiques micrométastase, cellules circulant tumorales, qRT-PCR, E6 
et E7 oncoprotéine, enrichissement immunomagnétique, détection moléculaire. 
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ABSTRACT 
Background:  
Uterine cervical cancer (UCC) is the fourth common cancer affecting women worldwide. In 
general, the dissemination of cancer cells (metastasis) directly impacts our ability to cure cancer. 
Lymph node metastasis is an important independent risk factor associated with poor prognosis.  
The detection of circulating tumor cells (CTCs) also has prognostic value in many other cancers 
(Breast, lung, colon and prostate), but this is not yet used for UCC. Currently, the treatment of 
UCC is guided by traditional clinical and pathological assessment. Advancement in molecular 
techniques for the detection of rare disseminated cancer cells could vastly improve disease 
management. 
Objective: 
To use molecular biomarkers to optimize the enrichment and the detection of tumor cells in the 
bloodstream and in lymph node (LN) for UCC patients.  
Material & Methods: 
Series of sequential dilution of mixed population of UCC HeLa/CaSki cells and non-cancerous 
HCA2-hTERT cells imitating micrometastatic LN were prepared fresh or embedded in paraffin 
blocks and subjected to RNA extraction. In CTCs spiking models, CaSki cells were serially 
diluted and spiked into human blood collected from healthy volunteers. Enrichment using red 
blood cells (RBC) lysis and RBC lysis combined with negative or positive magnetic enrichment 
were compared. E6, E7, CK19 and p16INK4a gene expression by Real-Time Quantitative Reverse 
Transcriptase polymerase chain reaction (qRT-PCR) were used to detect cancer cells. 
Result:  
HVP16/18 E6 & E7 mediated detection limits in fresh samples was 0.008% (1:12500 cells) 
compared to 0.02% and 0.05% (for HPV16 E6/E7 and HPV18 E6/E7 respectively) in paraffin 
blocks. In CTCs spiking model, qRT-PCR following RBC lysis alone or combined with negative 
or positive enrichment revealed detection limit of 50 cells per mL of blood for E6, E7, Ck19 and 
p16. The sensitivity of PCR increased with positive and negative enrichment by eliminating 
PBMC background.  
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Conclusion: 
qRT-PCR of HPV oncogenes expression  is more sensitive than pathological examination in 
detecting lymph node metastasis. qRT-PCR of HPV oncogenes, CK19, and p16 expression all 
demonstrated high sensitivity in detecting spiked cancer cell in paraffin blocks and in blood.   
 
Key words: diagnostic, uterine cervical carcinoma, pretherapeutic evaluation, viral oncogenes, 
lymph node micrometastasis, circulating tumor cells, qRT-PCR, E6 and E7 oncoprotein, 
immunomagnetic enrichment, molecular detection.   
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INTRODUCTION 
Uterine cervical cancer (UCC) is the fourth most common cancer affecting women worldwide 
and the fourth leading cause of cancer-related deaths in women [1]. Human papillomavirus 
(HPV) is the primary etiological risk factor for cervical cancer, and HPV is detected in 99.7% 
of cervical carcinomas [2]. The E6 and E7 oncoproteins encoded by high-risk HPV types are 
synergistically necessary and sufficient to induce cellular transformation and immortalization 
[3, 4]. E6 binds p53 and promotes ubiquitin-mediated degradation, while also inducing BAK 
(Bcl-2-homologous antagonist/killer)  degradation and telomerase activation; whereas, E7 binds 
and inactivates retinoblastoma tumor suppressor protein (Rb), leading to the release of the E2F 
transcriptional activator, a loss of cyclin-dependent kinase (CDK) inhibition, and the indirect 
upregulation of the cellular tumor suppressor p16INK4A. This process potentiates genomic 
instability, cellular immortalization, and malignant transformation [5-10]. Notably, abolishing 
E6 and E7 expression in cervical cancer cell lines lead to growth arrest, cellular senescence, and 
apoptosis highlighting the dependence of UCC cells for these viral oncogenes [11-16].  
Early-stage therapy can consist of surgical or primary radiotherapy, which have 
comparable outcomes but different toxicity profiles [17]. Approximately 50% of patients require 
adjuvant radiotherapy for risk factors identified from primary surgery and pathological 
examination including pelvic lymph node metastasis, parametrial involvement, and positive 
resection margins; however, this combination of surgery and radiotherapy is associated with 
increased morbidity [17-19].  
Pelvic lymph node metastasis is an independent prognostic factor associated with 
decrease disease-free interval and survival, and occurs in about 21% of patients with early-stage 
UCC [20]. Radiological assessment lacks the sensitivity to detect lymph node metastasis [21]. 
The sensitivity of PET/CT scan, MRI and CT to detect lymph node metastases ≥5 mm in 
diameter is 75%, 56% and 58% respectively, and those smaller falls below the detection limit 
of these technologies [22]. Approximately 15% of stage I-B UCC patients relapse, despite the 
absence of lymph node metastasis by routine histopathological examination and clear surgical 
margins [18]. A retrospective re-examination of surgically resected pelvic lymph nodes detected 
micrometastasis in 22.2% of cases and reported a range of 3.8-23.9% from a review of current 
literature [23, 24]. Micrometastases and isolated tumor cells (ITC) are defined as tumor clusters 
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between 0.2-2 mm and ≤0.2 mm in size, respectively; with the later found in 10-90% of lymph 
nodes deemed negative by routine histological examination [25, 26]. In cervical carcinoma, 
micrometastasis is an independent risk factor associated with lower overall survival [27, 28]. 
The advent of ultrastaging has improved detection rate of lymph node metastasis [29, 30]; 
however, the technique is cumbersome and requires the examination of several slides. Sentinel 
lymph node (SLN) mapping has emerged to improve detection rates and reduce complications 
associated with complete pelvic lymphadenectomy [30-32]. The SLN is the first lymph node in 
the lymphatic pathway draining a tumor and, if that lymph node is negative, then all others are 
assumed negative. However, the performance of SLN mapping depends on multiple factors 
including the technique used to identify the SLN [27, 33], surgical experience [34], tumor 
volume [35, 36], and pathological examination [27, 37]. A large multicenter retrospective study 
determined that SLN mapping and ultrastaging had a sensitivity and false negative rate for 
metastasis of 91% and 2.8%, respectively [38].  
Cytokeratin 19 (CK19) expression is prevalent in epithelial tumor cells and has recently 
been investigated as a potential tumor marker. A previous study using CK19 qRT-PCR to detect 
lymph node micrometastasis in cervical cancer found expression in ~50% of lymph nodes. 
Moreover, 44% of histologically negative lymph nodes were positive for CK19, a result that 
correlated with clinicopathological features [39]. In breast carcinoma, a one-step nucleic acid 
amplification assay (OSNA) for CK19 has been used for the rapid intraoperative detection of 
lymph node metastasis with a sensitivity of 93.3% [40], whereas   the analysis of frozen sections 
has a 58 % sensitivity for detecting nodal micrometastasis [41]. A similar result for the low 
performance of frozen section analysis has been reported for UCC [42-44], suggesting that 
CK19 OSNAs may be valuable for the management uterine cervical cancer.  
Studies addressing the presence of circulating tumor cells (CTCs) in UCC are scarce. 
Pao et al. previously reported on the detection of CTCs in 92% patients with metastatic cervical 
cancer by HPV16 E6  RT-PCR [45]. In follow up by the same group, the HPV16 and/or 18 E6 
oncogenes expression were detected in 51.4% of locally advanced UCC and was associated with 
a higher risk of recurrence, distant metastasis, and lower overall survival [46]. 
Overall, the development of sensitive molecular biomarkers could dramatically improve the 
diagnostic and treatment selection process for UCC patients.  Herein, we describe the detection 
of lymph node micrometastases and CTCs in experimental models using fresh material, 
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paraffin-embedded blocks, and blood using qRT-PCR for the HPV E6/E7, CK19, and p16INK4A 
gene expression.  
MATERIAL AND METHODS   
Cell Culture  
HeLa and HCA2-hTERT (obtained from ATCC) cell lines were cultured in Dulbecco's Modified 
Eagle Medium (DMEM) media and the CaSki cells (obtained from ATCC) in RPMI media. 
Media was supplemented with 8% FBS, 100 IU/mL penicillin, and 100 g/mL streptomycin. 
The cells were grown at 37°C in a humidified atmosphere of 5% CO2. Sub-confluent cells were 
passaged every two to three days using 0.05% trypsin supplemented with 0.53 mM EDTA. 
CTC Enrichment  
Blood from healthy volunteers were collected in EDTA-treated tubes and informed consent were 
obtained from the volunteers. CaSki cells were serially diluted and spiked into blood and 
enriched either using RBC lysis alone or in combination with negative or positive selection with 
αCD45 (leukocyte common antigen) or αEpCAM (epithelial cell adhesion molecule) antibodies, 
respectively. RBC lysis was performed with ACK lysis buffer as previously described [47]. 
Briefly, 10 mL buffer was added per mL of blood and incubated for 5 minutes at room 
temperature. Incubations were extended for an additional 5 minutes if lysis was incomplete. 
Cells then were collected by centrifugation at 400g for 5 minutes at 4°C and washed once with 
cold PBS before use in subsequent analyses or enrichment protocols. CD45-negative and 
EpCAM-positive selection was accomplished by magnetic separation with antibody-coated 
Dynabeads® following the manufacturer’s protocol. Briefly, cells were incubated with the 
respective Dynabeads for 30 minutes at 2-8°C, and then exposed to magnet for 10 minutes to 
deplete CD45-positive mononuclear cells or isolate EpCAM-positive cancer cells. Supernatants 
from both separations were transferred to new tubes. All samples were washed once with cold 
PBS prior to use in subsequent procedures. 
RNA Extraction  
RNA was isolated from freshly harvested cells and enriched with TRIzol® reagent using the 
manufacturer’s protocol, or extracted from formalin-fixed paraffin-embedded (FFPE) samples 
using the RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion, Inc.) with minor changes to 
the manufacturer’s protocol. Briefly, fifteen 10 µm paraffin sections for each sample were 
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subjected to proteinase digestion for one hour at 50°C, and left for additional 15 minute intervals 
until clear and fluid. The eluate was repurified with the RNeasy® MinutesElute™ Cleanup Kit 
(QIAGEN). The RNA quantity and purity was determined by A260/280 ratios as measured on 
a spectrophotometer. RNA was stored at -80°C until further analysis. 
Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
Superscript III First-strand Synthesis Supermix (Invitrogen) was used to synthesize cDNA per 
manufacturer’s protocol. Reactions were performed with ≤1 μg RNA in a 20 µL reaction 
volume. Gene expression was measured using TaqMan® Assays. Oligo Analyzer 3.1 and 
BLAST software (Basic Local Alignment Search Tool) were used to verify the specificity of 
primers and probes sequences for E6, E7, CK19 and p16INK4A (Table IV-I). Probes and primers 
were purchased from Integrated DNA Technology. Expression of 18S ribosomal RNA and/or 
TATA-box binding protein (TBP) served as internal controls. Platinum® Quantitative PCR 
SuperMix-UGD was used for qRT-PCR reactions. cDNA (≤150 ng) was amplified in a 15μL 
reaction mixture with final concentrations of 4 mM MgCl2, 0.2 µM probe, and 0.2 µM of each 
primer. Reactions were run on a StepOnePlus™ Real time PCR instrument with initial 
incubations at 50°C for 2 minutes and 95°C for 10 minutes, followed by 40 thermocycles of 
95°C for 15 seconds and 60°C for one minute. Reactions were performed in triplicate with 
positive, negative, and no template controls (NTC). Data was analyzed with StepOne™ Software 
using the comparative Ct method. 
Preparation of Formalin-Fixed Paraffin-Embedded (FFPE) Lymph Node models  
Paraffin block containing 50/50 mixes of HeLa-HPV16/18+/CaSki-HPV16+ or CaSki-
HPV16+/HCA2-hTERT-HPV- cells were made to test for HPV-18 and HPV-16 detection, 
respectively. Blocks of pure CaSki or HCA2-hTERT cells were made to serve as negative 
controls for HPV18 and HPV16, respectively. Of note, CaSki cell line contains an integrated 
HPV16 genome as well as sequences related to HPV18; however, HPV16 RNA is solely 
expressed [48, 49]. Mixtures of 106 total cells (5 × 105 per cell type) were vortexed and 
centrifuged at 1500 RPM for 10 minutes. Cell pellets were suspended in 500 µL 10% formalin, 
transferred tubes containing well-shaped solid histogel and centrifuged for 15 minutes at 2500 
RPM. The resulting supernatant was aspirated and 2-5 mL of histogel was added to enclose the 
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pellet. The histogel was allowed to solidify for 20 minutes, followed by the addition of 1-2 mL 
10% formalin. The blocks were incubated overnight at 4°C prior to paraffin embedding. 
Correlation of the Mixed Cell Model to Lymph Node Metastasis 
Macrometastasis, micrometastasis, and ITCs in lymph nodes are defined as tumor clusters >2 
mm, 0.2-2 mm, and <0.2 mm, respectively [25, 26]. Knowing that the upper limit of normal 
pelvic lymph node size is one cm [50], we calculated the lymph node volume using the following 
formula: 4/3 × 3.14 × R3, where R is defined as the radius and equals half the diameter. We 
hypothesize that macrometastases, micrometastases, and ITCs occupy >0.8%, 0.008-0.8%, and 
less than 0.008% of lymph node volumes, respectively. Calculations are presented in Table IV-
II. 
RESULTS 
Analysis of HPV16/18 E6/E7 oncogenes expression from a mix population of fresh cells 
Serial dilutions of CaSki UCC cells in HCA2-hTERT and HeLa UCC cells in CaSki UCC cells 
were prepared in order to determine the lower detection limit of E6/E7 expression by qRT-PCR. 
All values were normalized to ribosomal 18s gene expression to eliminate variation in the RNA 
quantity between samples and the expression of both markers decreased with increased serial 
dilutions, indicating successful dilution schemes. We determined that for HPV16 E7 and HPV18 
E6 and E7, the lower detection limit for HPV16 E7, HPV18 E6, and HPV18 E7 expression is 
0.008%, which is significantly different from the HCA2-hTERT and CaSki negative controls, 
respectively (Figure IV-1) (Table IV-III). HPV18 E6 and E7 expression was undetectable in 
pure CaSki cells; however, weak basal non-specific HPV16 E6 and E7 expression was observed 
in HCA2-hTERT cells.  
HPV 16/18 E6 and E7 oncogenes expression from FFPE cell mixtures 
To further determine the ability to detect metastatic cancer cells in FFPE lymph nodes using 
molecular biomarker expression, we examined the E6/E7 qRT-PCR sensitivity threshold for 
RNA extracted from FFPE lymph node models. First, multiple reference genes were assessed 
to identify reliable constitutively expressed internal reference genes following FFPE-
deparaffinization, resulting in the selection of 18s ribosomal RNA. In addition, we observed a 
1000-fold lower signal from RNA extracted following FFPE-deparaffinization process when 
compared to that obtained from fresh material. We then serially diluted RNA extracted from 
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50/50 positive-negative cell population mixes into RNA extracted from negative cell 
populations and made cDNA for subsequent qRT-PCR analysis to detect E6 and E7 oncogenes 
expression. Notably, the expression of both markers diminished with progressive cell dilutions 
and was detectable down to a dilution factor of 0.02% for HVP16 E6/E7 (Figure IV-2; A-B) and 
0.05% for HPV18 E6/E7 (Figure IV-2; C-D) (Table IV-IV).  
CTCs detection using molecular biomarkers 
We next defined the lower detection limits of the UCC molecular biomarkers E6, E7, CK19 and 
p16INK4A for identifying CTCs, and evaluated their dependency on various methods of CTCs 
enrichment. Figure IV-3;A-B show the relative detection of HPV16 E6 and E7 oncogenes 
expression normalized to TBP following enrichment using RBC lysis reagent. TBP was selected 
as an internal reference to avoid multiplex PCR saturation phenomenon associated with 
abundant levels of ribosomal 18s. A decrease in both expression markers correlated with the 
progressive dilutions of cancer cells down to 50 spiked cancer cells per mL of blood and a 1000-
fold difference was observed between the 50 cells/mL positive sample and negative control, 
with an increased sensitivity for E7 oncogene expression compared to E6. Similarly, p16INK4A 
expression decreased with serial dilutions of cancer cells down to a level approximating 50 
cells/mL of blood (Figure IV-3C). Due to its endogenous expression in normal cells, a low level 
of p16INK4A expression was detected in the negative blood control, but to a low level comparable 
to expectations for normal cellular physiology [51]. Significantly, a 1000-fold difference was 
observed between the 50 cells/mL positive sample and negative control. Finally, CK19 
expression shown in Figure 3D reveal a sensitivity down to 50 cells/mL of blood and similarly 
a 1000-fold difference was observed between the 50 cells/mL positive sample and negative 
control 
Following CTC negative enrichment, E6 and E7 oncogenes expression was analyzed in 
the enriched, CD45-negative and the resulting CD45-positive PBMC population and normalized 
to 18S ribosomal RNA expression (Because of very low amounts of starting material, E6 and 
E7 multiplex PCR detection were performed simultaneously and normalized to ribosomal 18S 
expression). Both markers correlated with the serial dilutions of cancer cells down to 50 spiked 
cells per mL of blood (Figure IV-4A). Non-normalized cycle threshold values were used as the 
variation of ribosomal 18s expression across samples caused by extremely low quantities of 
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recovered RNA prevented effective normalization. Similar pattern trended in the CD45-positive 
population, suggesting that a fraction of tumor cells either attached to CD45-postive cells or 
where non-specifically bound by the anti-CD45 antibodies (Figure IV-4B).  
When comparing the positive versus negative isolation methods, we determined that 
both techniques were capable of detecting spiked cancer cells down to 50 cells/mL (Figure IV- 
5; A,C). However, we found that our positive enrichment method was able to recover more cells 
than the negative enrichment method. As for CD45-based negative enrichment, E6 and E7 
oncogenes expression was also observed in the EpCAM-negative cell fraction isolates (Figure 
IV-5; D,E), suggesting that some tumor cells lacked EpCAM expression. Nevertheless, both 
enrichment techniques improved the qRT-PCR sensitivity by eliminating the PBMC 
background noise.  
DISCUSSION AND CONCLUSIONS 
UCC is the fourth most common cancer in woman worldwide. Surgery is the primary standard 
of care for early-stage UCC, and is supplemented with adjuvant radiotherapy based lymph node 
status, positive margins, and parametrial invasion as determined by histopathological 
assessment. Lymph node micrometastasis is an independent risk factor associated with reduced 
overall survival [24, 28]. Approximately 15% of stage IB patients relapse, despite negative LN 
and clear surgical margins [18]. Pathologists have an ~1% chance in detecting micrometastasis 
using conventional H&E staining [52]. SLN mapping and molecular ultrastaging has improved 
the detection rate of micrometastases, yet detection can still vary between 19-95% depending 
on methods used [29].  
 Advances in molecular biology techniques and applications have improved the detection 
of metastatic cancer in both sensitivity and specificity. Here, we describe a model to estimate 
the size of metastases harbored in a one cm3 lymph node. Macrometastases is more than 2 mm 
in size and occupy more than 0.8% of one cm3 lymph node; micrometastases is 0.2-2 mm in size 
and occupy 0.008-0.8% of one cm3 lymph node and ITC is ≤ 0.2 mm in size and occupy ≤ 
0.008% of one cm3 lymph node (Table IV-III).  Through our analyses, we purport that analysis 
of HPV E6/E7 oncogenes expression by qRT-PCR is sufficient to detect a mass of tumor cells 
in  equivalent to macrometastases (> 0.8%) and micrometastases (0.008-0.8%), but not ITCs (< 
0.008%), which fell below the detection limits. 
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FFPE tissues are widely used for histological diagnosis. The identification and validation 
of molecular markers using FFPE tissue is an area of intense research activity given the amount 
of tumor samples preserved in this manner, and any molecular methods successful at this type 
of analysis would allow the use of retrospectively banked pathology samples to clearly define 
the clinical impact rare cancer cells. The mRNA extracted from FFPE tissue is difficult to 
analyze, since formalin fixation results in protein/nucleic acid crosslinking and RNA 
degradation [53]. In our study, we observed lower sensitivity of qRT-PCR with RNA extracted 
from FFPE tissue compared to that extracted from fresh material. Notably, E6 and E7 oncogenes 
expression was 1000-fold less in FFPE cells compared to fresh isolates. RNA extracted from 
FFPE tissue had an A260/280 ≥ 1.9 and RNA disintegration was excluded by agarose gel 
electrophoresis, suggesting that RNA fragmentation may have occurred during the 
deparaffinization process. HPV16 and 18 E6/E7 oncogenes expression by qRT-PCR is sufficient 
to detect a mass of tumor cells in  equivalent to 0.02% and 0.05% of a one cm3 lymph node 
respectively. Because this detection limit is in the middle of the size of the micrometastasis 
category, the probability of detecting micrometastasis using the HVP16 and HVP18 oncogenes 
expression from FFPE tissue would be 98% and 95%, respectively, potentially missing the 
smaller micrometastasis and clearly falling short of ITC detection.   
In this study, we also sought to determine the sensitivity and specificity of known cancer 
biomarkers for identifying UCC CTCs using qRT-PCR. The E6 and E7 oncogenes expression 
exhibited the highest specificity and sensitivity with the ability to detect 50 cells/mL of blood. 
Furthermore, a ≥1000-fold difference between the 50 cells/mL positive sample and negative 
control implies a greater sensitivity probably approaching 1 cell/mL of blood. Specifically, the 
X cycle threshold difference between the positive and the negative signals can be directly 
interpreted to a value of Y (log2 of Y) and used to be divided by 50 cells/mL to obtain a value 
of Z, which equal to one cell/mL. Both positive and negative enrichment methods improved the 
PCR sensitivity by eliminating PBMCs derived RNA background. However, positive 
enrichment recovered most cancer cells and provide the additional advantage of allowing the 
potential analysis of tumor gene expression on a highly pure isolate. It is important to note that 
EpCAM downregulation during EMT likely results in lower EpCAM expression and is a 
limitation of this technique since some cancer cells could be loss in the EpCAM negative 
fraction as observed in figure (5 B and D). In CD45-mediated negative enrichment, E6 and E7 
52 
 
oncogenes expression in the resultant cell population indicated that tumor cells attached or were 
engulfed by macrophages. The prognostic value of cells expressing both CD45 and tumor 
markers have not yet been determined [54]. Furthermore, p16INK4A was sufficient to detect UCC 
cancer cells down to lower than 50 cells/mL of blood and (potentially approaching 1 cell/mL of 
blood, see above); however, endogenous p16INK4A expression could make it difficult to 
distinguish CTCs from normal cells unless appropriate cutoff median expression values are 
established. Setting these values may be further complicated since p16INK4A expression varies 
depending on normal physiological activity and can increase with age and smoking [51]. CK19 
had similar sensitivity to the E6 and E7 oncogenes expression; however, the marker is not 
specific to tumors and can be found in isolates from normal individuals [55]. We postulate that 
if an appropriate cutoff median expression value is established for a normal expression level, 
then this marker may be used for CTC detection. Using RT-PCR with established cutoff value 
to detect CK19 transcript in breast cancer patients, 2.2% of healthy females were positive 
compared to 31% and 40% of those with early and metastatic breast cancer, respectively. 
Moreover, the CK19 expression levels were significantly higher in breast cancer patient 
compared to those in the control group [56].  There are a limited number of studies addressing 
the detection of CTCs in UCC. Pao et al. used a Ficoll-Paque density gradient medium to enrich 
CTCs prior to HPV E6 oncogene expression analysis by RT-PCR, which was detected in 92% 
of stage IV-B UCC [45]. In follow up by the same group, HPV16/18 E6 expression was detected 
in 51.4% of locally advanced UCC cases and was associated with a higher risk of recurrence, 
distant metastasis, and lower overall survival [46]. In contrast, a study using Ficoll-Paque 
isolation followed by EpCAM-mediated positive selection was sufficient to detect ≥3.33 
CTCs/mL with an average recovery was 50%. It was also capable of detecting CTCs in 23% 
patients with locally advanced UCC stage [57]. Digital-Direct-RT-PCR for HPV16/18 E6 
expression imparted a sensitivity of one CTC per 500,000 normal cells and the ability to detect 
5 CTCs/mL of blood [58]. In addition, the PCR sensitivity was inversely related to the 
background number of PBMCs. Finally, CK19 nested RT-PCR was shown to detect CTCs in 
21.4% of stage IB-IIB patient; although, its expression did not correlate with any 
clinicopathological parameters [59]. 
In conclusion, qRT-PCR for E6 and E7 oncogenes expression is a sensitive and specific 
technique to detect CTCs and small lymph node metastases in UCC. Notably, we demonstrate 
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the ability to detect lymph node micrometastases equivalent to 0.2 mm in size and circulating 
tumor cells approaching 1 cell/mL of blood. The sensitivity of qRT-PCR in detecting HPV16/18 
E6 and E7 is markedly affected by formalin fixation process as expected and is sufficient to 
detect a mass of tumor cells in equivalent to 0.02% and 0.05% of a one cm3 lymph node 
potentially missing the smaller micrometastasis and clearly falling short of ITC detection. We 
also show that CK19 and p16INK4A can be used as adjuvant markers to verify CTCs detection, 
provided that appropriate cutoff median expression values are determined to differentiate 
between normal and malignant expression levels. 
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FIGURE AND TABLE LEGENDS: 
Figure IV-1: E6/E7 oncogenes expression in a mix of cell populations containing HPV 
positive and/or negative cells. 
RNA was extracted from freshly mixed cell populations containing UCC cancer cell lines. E6 
and/or E7 oncogenes expression was then analyzed by qRT-PCR. (A) E6 oncogene expression 
in HPV16-negative CaSki UCC and HPV16-positive HCA2-hTERT immortalized fibroblast 
cells demonstrating detection limit at 0.008% (p < 0.01). (B) E6 and (C) E7 oncogenes 
expression in HPV18-negative CaSki and HPV18-positive HeLa cells demonstrating detection 
limit at 0.008% for both markers (p < 0.05). Values represent the mean ± SD for a minimum of 
two experimental replicates.  
 
Figure IV-2: E6/E7 oncogenes expression from formalin-fixed, paraffin-embedded UCC 
mixtures.  
Serial dilutions of RNA extracted from formalin-fixed, paraffin-embedded blocks comprised of 
a 50/50 mix of UCC cells and human fibroblasts were examined for E6 and E7 oncogenes 
expression by qRT-PCR. (A) E6 and (B) E7 expression from HPV16-positive CaSki UCC cells 
mixed with HCA2-hTERT fibroblasts demonstrating detection limit at 0.02% for both markers. 
(C) E6 and (D) E7 expression from HPV18-negative CaSki mixed with HPV18-positive HeLa 
cells demonstrating detection limit at 0.05% for both markers. Values represent the mean ± SD 
for a minimum of three experimental replicates. 
 
Figure IV-3: Expression of E6/E7 pathway constituents from CaSki cells spiked into 
human blood following isolation by RBC lysis. 
The expression of (A) E6, (B) E7, (C) p16, and (D) CK19 were analyzed by qRT-PCR from 
RNA extracted from CaSki cells isolated by RBC lysis enrichment. CaSki represents RNA 
extracted from pure cancer cells demonstrating detection limit at 50 cancer-cells/mL of blood% 
for all markers. Values represent the mean ± SD for a minimum of three experimental replicates. 
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Figure IV-4: E6/E7 expression in CaSki cells spiked into human blood following negative 
enrichment. E6 and E7 expression in was analyzed by qRT-PCR in (A) CD45-negative CaSki 
cells and (B) the depleted CD45-positive population.  
 
Figure IV-5: Comparison E6/E7 expression detection from CaSki cells spiked into human 
blood following positive or negative enrichment. E6 and E7 expression were analyzed 
following positive or negative enrichment with αEpCAM or αCD45, respectively. (A-B) E6 and 
(C-D) expression in (A, C) EpCAM-positive and CD45-negative isolates, and (B, D) EpCAM-
negative and CD45-positive isolates.  
 
Table IV-I: Sequence of primers and TaqMan probes  
Table IV-II: Calculation of micrometastatic focus volume in one cm lymph node. 
Table IV-III: Detection limit of HVP oncogenes expression in fresh RNA. 
Table IV -IV: Detection limit of HPV oncogenes expression in RNA extracted from FFPE 
cells block. 
 
  
56 
 
Figure IV.1 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
C 
 
  
   * 
 * 
  * 
57 
 
Figure IV.2 
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Table IV-I 
Genes Sequence (5’-3’) Location Product size (bp)  
18s 
Forward 
Reverse  
Probe  
 
CGGCTACCACATCCAAGGAA 
CGCTATTGGAGCTGGAATTA 
TGCTGGCACCAGACTTGCCCTC 
450-646 197 
CK-19 
Forward 
Reverse  
Probe 
 
TCGACAACGCCCGTCTG 
CCACGCTCATGCGCAG 
CCTGTTCCGTCTCAAACTTGGTTCGG 
606-680 75 
HPV16 E6 
Forward 
Reverse  
Probe 
 
AATGTTTCAGGACCCACAGG 
CTCACGTCGCAGTAACTGTTG 
AGCGACCCAGAAAGTTACCACAGTTATG 
103-226 124 
HPV16 E7 
Forward 
Reverse  
Probe 
 
CAAGCAGAACCGGACAGA 
GTCTACGTGTGTGCTTTGTA 
CAAGTGTGACTCTACGCTTCGGTTGTG 
691-786 96 
HPV18 E6 
Forward 
Reverse  
Probe 
 
AACACGGCGACCCTACAA 
CTGTCTCTATACACCACAATAATC 
CGGAACTGAACACTTCACTGCAAGACATA 
125-280 156 
HPV18 E7 
Forward 
Reverse  
Probe 
 
AGCGACTCAGAGGAAGAAA 
CGTCTGCTGAGCTTTCTACTAC 
CTCAATTCTGGCTTCACACTTACAACACA 
683-833 151 
P16 INK4A 
Forward 
Reverse  
Probe 
 
CTGCCCAACGCACCGAATA 
GCGCTGCCCATCATCATGA 
CTGGATCGGCCTCCGACCGTA 
415-476 62 
TBP 
Forward  
Reverse 
Probe  
 
ACAGGAGCCAAGAGTGAA 
AAACCCAACTTCTGTACAAC 
ACAGTCCAGACTGGCAGCAAGAAAATA 
743-816 
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Table IV-II 
 
 
Size Volume 
Percentage of tumor occupying a 1 
cm LN 
Normal lymph Node 1 cm 523.6 mm3 N/A 
Macrometastasis  >2 mm >4.2 mm3 > 0.8% 
Micrometastasis 
  Upper limit  
  Lower limit  
 
2 mm 
0.2 mm 
 
4.2 mm3 
0.00418 mm3 
 
0.8% 
0.008% 
ITC  0.2 mm  0.00418 mm3  0.008% 
 
Table IV-III 
Detection limit in fresh tissue 
 E6 E7 
HPV16 0.008% 0.008% 
HPV18 0.008% 0.008% 
 
Table IV-IV 
Detection limit in FFPE 
 E6 E7 
HPV16 0.02% 0.02% 
HPV18 0.05% 0.05% 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
BIBLIOGRAPHY 
 
1. Incidence/mortality data. Ferlay J, S.I., Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin 
DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on 
Cancer; 2013. Available from: http://globocan.iarc.fr. 
2. Walboomers, J.M., et al., Human papillomavirus is a necessary cause of invasive cervical cancer 
worldwide. J Pathol, 1999. 189(1): p. 12-9. 
3. Hawley-Nelson, P., et al., HPV16 E6 and E7 proteins cooperate to immortalize human foreskin 
keratinocytes. EMBO J, 1989. 8(12): p. 3905-10. 
4. Munger, K., et al., The E6 and E7 genes of the human papillomavirus type 16 together are 
necessary and sufficient for transformation of primary human keratinocytes. J Virol, 1989. 
63(10): p. 4417-21. 
5. Munger, K. and P.M. Howley, Human papillomavirus immortalization and transformation 
functions. Virus Res, 2002. 89(2): p. 213-28. 
6. zur Hausen, H., Papillomaviruses and cancer: from basic studies to clinical application. Nat 
Rev Cancer, 2002. 2(5): p. 342-50. 
7. Khleif, S.N., et al., Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-
mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A, 1996. 93(9): p. 
4350-4. 
8. Kiyono, T., et al., Both Rb/p16INK4a inactivation and telomerase activity are required to 
immortalize human epithelial cells. Nature, 1998. 396(6706): p. 84-8. 
9. Vande Pol, S.B. and A.J. Klingelhutz, Papillomavirus E6 oncoproteins. Virology, 2013. 445(1-
2): p. 115-37. 
10. Roman, A. and K. Munger, The papillomavirus E7 proteins. Virology, 2013. 445(1-2): p. 138-
68. 
11. Desaintes, C., et al., Expression of the papillomavirus E2 protein in HeLa cells leads to 
apoptosis. EMBO J, 1997. 16(3): p. 504-14. 
12. Hu, G., et al., Suppression of tumorigenesis by transcription units expressing the antisense E6 
and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and 
the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther, 
1995. 2(1): p. 19-32. 
13. Hwang, E.S., et al., Inhibition of cervical carcinoma cell line proliferation by the introduction 
of a bovine papillomavirus regulatory gene. J Virol, 1993. 67(7): p. 3720-9. 
14. Wells, S.I., et al., Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and 
p21(CIP)-dependent pathways. EMBO J, 2000. 19(21): p. 5762-71. 
15. Wu, L., et al., E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical 
carcinoma cells following repression of human papillomavirus oncogene expression. Mol Cell 
Biol, 2000. 20(19): p. 7059-67. 
16. von Knebel Doeberitz, M., et al., Inhibition of tumorigenicity of cervical cancer cells in nude 
mice by HPV E6-E7 anti-sense RNA. Int J Cancer, 1992. 51(5): p. 831-4. 
17. Landoni, F., et al., Randomised study of radical surgery versus radiotherapy for stage Ib-IIa 
cervical cancer. Lancet, 1997. 350(9077): p. 535-40. 
18. Delgado, G., et al., Prospective surgical-pathological study of disease-free interval in patients 
with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. 
Gynecol Oncol, 1990. 38(3): p. 352-7. 
19. Yuan, C., et al., Recurrence and survival analyses of 1,115 cervical cancer patients treated with 
radical hysterectomy. Gynecol Obstet Invest, 1999. 47(2): p. 127-32. 
65 
 
20. Benedetti-Panici, P., et al., Lymphatic spread of cervical cancer: an anatomical and pathological 
study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. 
Gynecol Oncol, 1996. 62(1): p. 19-24. 
21. Selman, T.J., et al., Diagnostic accuracy of tests for lymph node status in primary cervical 
cancer: a systematic review and meta-analysis. CMAJ, 2008. 178(7): p. 855-62. 
22. Sironi, S., et al., Lymph node metastasis in patients with clinical early-stage cervical cancer: 
detection with integrated FDG PET/CT. Radiology, 2006. 238(1): p. 272-9. 
23. Cote, R.J., et al., Role of immunohistochemical detection of lymph-node metastases in 
management of breast cancer. International Breast Cancer Study Group. Lancet, 1999. 
354(9182): p. 896-900. 
24. Horn, L.C., et al., Detection of micrometastases in pelvic lymph nodes in patients with carcinoma 
of the cervix uteri using step sectioning: Frequency, topographic distribution and prognostic 
impact. Gynecol Oncol, 2008. 111(2): p. 276-81. 
25. Hermanek, P., et al., International Union Against Cancer. Classification of isolated tumor cells 
and micrometastasis. Cancer, 1999. 86(12): p. 2668-73. 
26. Schwartz, G.F., et al., Proceeding of the consensus conference of the role of sentinel lymph node 
biopsy in carcinoma or the breast April 19-22, 2001, Philadelphia, PA, USA. Breast J, 2002. 
8(3): p. 124-38. 
27. Darai, E., et al., Sentinel lymph node biopsy in gynaecological cancers: the importance of 
micrometastases in cervical cancer. Surg Oncol, 2008. 17(3): p. 227-35. 
28. Cibula, D., et al., Prognostic significance of low volume sentinel lymph node disease in early-
stage cervical cancer. Gynecol Oncol, 2012. 124(3): p. 496-501. 
29. Euscher, E.D., et al., Ultrastaging improves detection of metastases in sentinel lymph nodes of 
uterine cervix squamous cell carcinoma. Am J Surg Pathol, 2008. 32(9): p. 1336-43. 
30. Cormier, B., et al., Establishing a sentinel lymph node mapping algorithm for the treatment of 
early cervical cancer. Gynecol Oncol, 2011. 122(2): p. 275-80. 
31. Balega, J. and P.O. Van Trappen, The sentinel node in gynaecological malignancies. Cancer 
Imaging, 2006. 6: p. 7-15. 
32. Gortzak-Uzan, L., et al., Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage 
cervical cancer: is it time to change the gold standard? Gynecol Oncol, 2010. 116(1): p. 28-32. 
33. Eiriksson, L.R. and A. Covens, Sentinel lymph node mapping in cervical cancer: the future? 
BJOG, 2012. 119(2): p. 129-33. 
34. Plante, M., et al., Laparoscopic sentinel node mapping in early-stage cervical cancer. Gynecol 
Oncol, 2003. 91(3): p. 494-503. 
35. Zarganis, P., et al., The sentinel node in cervical cancer patients: role of tumor size and invasion 
of lymphatic vascular space. In Vivo, 2009. 23(3): p. 469-73. 
36. Altgassen, C., et al., Multicenter validation study of the sentinel lymph node concept in cervical 
cancer: AGO Study Group. J Clin Oncol, 2008. 26(18): p. 2943-51. 
37. Diaz, J.P., et al., Sentinel lymph node biopsy in the management of early-stage cervical 
carcinoma. Gynecol Oncol, 2011. 120(3): p. 347-52. 
38. Cibula, D., et al., Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the 
false-negative rate and improving the detection of micrometastasis. Gynecol Oncol, 2012. 
127(3): p. 462-6. 
39. Van Trappen, P.O., et al., Molecular quantification and mapping of lymph-node micrometastases 
in cervical cancer. Lancet, 2001. 357(9249): p. 15-20. 
40. Tsujimoto, M., et al., One-step nucleic acid amplification for intraoperative detection of lymph 
node metastasis in breast cancer patients. Clin Cancer Res, 2007. 13(16): p. 4807-16. 
41. Tanis, P.J., et al., Frozen section investigation of the sentinel node in malignant melanoma and 
breast cancer. Ann Surg Oncol, 2001. 8(3): p. 222-6. 
66 
 
42. Slama, J., et al., High false negative rate of frozen section examination of sentinel lymph nodes 
in patients with cervical cancer. Gynecol Oncol, 2013. 129(2): p. 384-8. 
43. Fader, A.N., et al., Sentinel lymph node biopsy in early-stage cervical cancer: utility of 
intraoperative versus postoperative assessment. Gynecol Oncol, 2008. 111(1): p. 13-7. 
44. Bats, A.S., et al., Diagnostic value of intraoperative examination of sentinel lymph node in early 
cervical cancer: a prospective, multicenter study. Gynecol Oncol, 2011. 123(2): p. 230-5. 
45. Pao, C.C., et al., Detection of human papillomavirus mRNA and cervical cancer cells in 
peripheral blood of cervical cancer patients with metastasis. J Clin Oncol, 1997. 15(3): p. 1008-
12. 
46. Tseng, C.J., et al., Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood 
of advanced cervical cancer patients and its association with prognosis. J Clin Oncol, 1999. 
17(5): p. 1391-6. 
47. Wentzensen, N., S. Vinokurova, and M.v.K. Doeberitz, Systematic Review of Genomic 
Integration Sites of Human Papillomavirus Genomes in Epithelial Dysplasia and Invasive 
Cancer of the Female Lower Genital Tract. Cancer Research, 2004. 64(11): p. 3878-3884. 
48. Pater, M.M. and A. Pater, Human papillomavirus types 16 and 18 sequences in carcinoma cell 
lines of the cervix. Virology, 1985. 145(2): p. 313-8. 
49. Yee, C., et al., Presence and expression of human papillomavirus sequences in human cervical 
carcinoma cell lines. Am J Pathol, 1985. 119(3): p. 361-6. 
50. Torabi, M., S.L. Aquino, and M.G. Harisinghani, Current concepts in lymph node imaging. J 
Nucl Med, 2004. 45(9): p. 1509-18. 
51. Liu, Y., et al., Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human 
aging. Aging Cell, 2009. 8(4): p. 439-48. 
52. Gusterson, B.A., et al., Occult axillary lymph-node micrometastases in breast cancer. The 
Lancet, 1990. 336(8712): p. 434-435. 
53. Srinivasan, M., D. Sedmak, and S. Jewell, Effect of fixatives and tissue processing on the content 
and integrity of nucleic acids. The American journal of pathology, 2002. 161(6): p. 1961-1971. 
54. van de Stolpe, A., et al., Circulating tumor cell isolation and diagnostics: toward routine clinical 
use. Cancer Res, 2011. 71(18): p. 5955-60. 
55. Burchill, S.A., et al., Detection of epithelial cancer cells in peripheral blood by reverse 
transcriptase-polymerase chain reaction. Br J Cancer, 1995. 71(2): p. 278-81. 
56. Stathopoulou, A., et al., Real-Time Quantification of CK-19 mRNA-Positive Cells in Peripheral 
Blood of Breast Cancer Patients Using the Lightcycler System. Clinical Cancer Research, 2003. 
9(14): p. 5145-5151. 
57. Weismann, P., et al., The detection of circulating tumor cells expressing E6/E7 HR-HPV 
oncogenes in peripheral blood in cervical cancer patients after radical hysterectomy. 
Neoplasma, 2009. 56(3): p. 230-8. 
58. Pfitzner, C., et al., Digital-Direct-RT-PCR: a sensitive and specific method for quantification of 
CTC in patients with cervical carcinoma. Sci Rep, 2014. 4: p. 3970. 
59. Yuan, C.C., et al., Detecting cytokeratin 19 mRNA in the peripheral blood cells of cervical 
cancer patients and its clinical-pathological correlation. Gynecol Oncol, 2002. 85(1): p. 148-
53. 
 
 
 
 
 
67 
 
CHAPTER V : RESULTS FROM UTERINE CERVICAL 
CANCER PATIENTS  
After we successfully demonstrated the ability of E6/E7, CK19 and P16INK4A in detecting spiked 
CaSki cell line and their detection limit using qRT-PCR, we sought to evaluate these molecular 
biomarkers to detect CTC in uterine cervical patients RNA extracted from non-magnetically 
enriched PBMC.  Ten patients with HPV16-positive uterine cervical tumor were recruited. The 
median patient age was 52 years at diagnosis [range 31–72]. Nine patients had squamous cell 
carcinoma, whereas one had adenocarcinoma. Five patients were stage IB, four were stage II, 
and one patient was stage 1A-1. Co-infection with multiple HPV types was detected in 50% of 
the patients. HPV35, 39, 52 and 58 are oncogenic types, while the others were considered low 
risk HPV types (Table V-1). None of the patients was tested positive for HPV18.   
Table V-I. Clinical characteristics of UCC patients.  
Age  52 years (median) 
Histology  
 Squamous carcinoma  
 Adenocarcinoma  
 
9  
1  
Stage 
 1A1 
 1B 
   IB1 
   IB 2 
 II 
   IIA 
   IIB 
 
1  
  
2 
3 
 
2 
2 
HPV type 
 HPV16  
 Multiple co-infection   
 
10  
5  
Total number  10 
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None of the patients had detectable E6 and E7 oncogenes expression in their enriched 
PBMC (Figure V-1). 
CK19 expression was undetectable in all control samples with the exception of CAm35 
and was extremely low compared to the CaSki cell line. In comparison, substantial CK19 
expression was detected in patients 5 and 27 all of which had stage II disease. CK19 transcripts 
were also detectable in patients 14 with stage IIA, patient 21 with stage IB-2 and patient 22 with 
stage IIA. However, these expression levels were similar to healthy volunteers. CK19 transcript 
was not detectable in patient ID 8, 35, 32, 33 and 37 (Figure V-2). 
P16INK4A transcripts were detectable at similar level across patients and control samples 
except patient ID 37 that had significantly higher expression level. However, the endogenous 
control of patient ID 37 had cycle threshold at 33.2 compared to 29 for other samples that explain 
the higher relative expression compared to the control samples (Figure V-3). 
 
 
Figure V.1. qRT-PCR of HPV16 E6/E7 in PBMC enriched from UCC patients. Multiplex E6 
and E7 qRT-PCR was performed in RNA extracted from non-magnetically enriched PBMC of 
uterine cervical patients by RBC lysis (except patient ID 8 and 5 in which Ficoll used to enrich 
PBMC). Sample IDs starting with the letter (C) collected from healthy female served as negative 
controls, while HPV16-positive CaSki cells served as a positive control. The y-axis denotes the 
log relative expression to TBP. 
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Figure V.2. qRT-PCR of CK19 in PBMC enriched from UCC patients. Multiplex CK19 qRT-
PCR was performed in RNA extracted from non-magnetically enriched PBMC of uterine 
cervical patients by RBC lysis (except patient ID 8 and 5 in which Ficoll used to enrich PBMC). 
Sample IDs starting with the letter (C) collected from healthy female served as negative controls, 
while HPV16-positive CaSki cells served as a positive control. The y-axis denotes the log 
relative expression to TBP. (p < 0.02) 
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Figure V.3. p16INK4A qRT-PCR analysis in PBMC enriched from UCC patients. Multiplexed 
qRT-PCR analysis for p16INK4A was performed in RNA extracted from non-magnetically 
enriched PBMCs from UCC patients by RBC lysis (except patient ID 8 and 5 in which Ficoll 
used to enrich PBMC). Sample IDs starting with the letter (C) collected from healthy females 
and HPV16-positive CaSki cells served as negative and positive controls, respectively. The y-
axis represents log relative expression to TBP endogenous control. 
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CHAPTER VI : DISCUSSION  
CTCs enrichment techniques 
1) Ficoll density enrichment 
Several techniques are available to enrich CTCs, with density separation and RBC lysis being 
the most common. Ficoll-Paque density gradients are widely used to enrich CTCs based on 
cellular density. The technique has an average recovery of only 70% due to cell loss during the 
process [190]. Our results are consistent with those previously published: cell loss is attributed 
to multiple washes, attachment to granulocytes and RBCs, and the wide variation in tumor cell 
density [26]. The detection limit of Ficoll-Paque enrichment with consistent reproducibility was 
1,000 cells/mL of blood with subsequent detection with qRT-PCR for HPV16 oncogenes 
expression, and exhibited an average recovery of 50%.  
In comparison, OncoQuick is a density medium that uses a porous barrier to prevent the 
PBMC interphase from mixing with granulocytes and RBC after centrifugation, whereas the 
FDA-approved CellSearch system using αEpCAM-conjugated nanoparticles to detect CTCs. 
These technologies identified CTCs in 23% and 54% of patients, respectively, with CellSearch 
recovering a greater percentage of targeted cells [191].  
2) RBC lysis  
To improve sensitivity and increase the recovery rates for our analysis, we used RBC lysis buffer 
independently or in cooperation with other enrichment methods. ACK buffer specifically lyses 
RBCs and leaves nucleated cells intact. The recovery rate is greater than 90% with a minimal 
effect on cell viability and cell surface antibody interaction [190].  
We found a detection limit of 50 CTCs/mL of blood following ACK lysis buffer 
enrichment. Isolated RNA had an A260/280 ≥ 1.8, demonstrating an adequate concentration and 
quality. Moreover, RNA integrity was verified by electrophoresis using Agilent Bioanalyzer and 
demonstrated intact 18S and 28S bands with no RNA disintegration. Furthermore, processing 
time and variation is minimized compared to Ficoll-Paque.  
3) Positive and negative enrichment  
To further enhance the sensitivity of the PCR and reduce the false positive rate as result of high 
background from PBMCs, we sought to determine the value of positive and negative 
enrichment.  
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Positive enrichment of cancer cells was based on EpCAM expression, an epithelial cell 
surface marker expressed by most cancers of epithelial cell origin [192]. The sensitivity of PCR 
in the detection of E6 and E7 improved when either positive or negative enrichment combined 
with RBC lysis as result of eliminating most of the PBMC-derived RNA.  
Positive enrichment yielded a highly purified cell fraction providing for gene expression 
profiling and the elimination of false positives. Disadvantages of positive enrichment include 
the inability to detect cancer cells of non-epithelial origin and those that have lost EpCAM 
expression during the process of EMT [35, 41-46], the latter of which might explain the 
detection of E6 and E7 in the supernatant fraction.  
Negative enrichment was based on the CD45-mediated depletion of macrophages, 
monocytes and lymphocytes. This technique isolated cancer cells regardless of their surface cell 
markers; however, we were able to detect E6 and E7 in the CD45-positive fraction. It has been 
demonstrated previously that most CTCs within the blood are either engulfed by macrophages 
or non-specific binding of anti-CD45 antibodies to Fc receptors, thus explaining the detection 
of HPV oncogenes expression in this fraction [27-30].  
CTCs detection  
1) Flow cytometry  
Advances in flow cytometry have permitted the analysis of thousand particles in a short time 
and is currently used for cell sorting, counting, and biomarker detection [193]. Fluorescence-
activated cell sorting (FACS) sorts cells based on their fluorescence following 
immunofluorescent labeling. For our studies, we used the CaSki cells tagged with GFP in order 
to differentiate them from normal PBMCs. The detection limit was 103-104 cells and 5,000 
cells/mL of blood following enrichment with Ficoll and RBC lysis buffer, respectively, when 
analyzed by single parameter flow cytometry. However, GFP is not normally expressed in 
human cancer cells. The sensitivity of flow cytometry can be improved with the use of multi-
parameter immunofluorescent labeling for multiple markers simultaneously. Hu et al. reported 
a sensitivity of one CTC per 100,000 normal cells in breast cancer [67].  
However, this platform lacks the sensitivity to isolate rare cells, requires a lengthy time 
for staining, necessitates the removal of RBCs, and samples must be analyzed on expensive 
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equipment [68]. Moreover, the identification of unpurified viable CTCs is less conducive to 
further molecular and biological characterization [19].  
 
2) Detection using molecular biomarkers in experimental spiking model 
a) HPV viral oncogenes 
The E6 and E7 oncogenes of HPV are constitutively expressed by most uterine cervical cancer 
cells to maintain malignant phenotype [118-123]. Moreover, these markers are not expressed by 
normal cell types, making them ideal markers for detecting CTCs in UCC.  
In an experimental spiking model, the sensitivity of PCR in detecting spiked CaSki cells 
following RBC lysis was 50 cells/mL with the ability to detect 1 cell/mL of blood based on the 
difference between the relative expressions of the lowest spiked cells and the negative control 
samples. Specifically, the X cycle threshold difference between the positive and the negative 
signals can be directly interpreted to a value of Y (log2 of Y) and used to be divided by 50 
cells/mL to obtain a value of Z, which equal to one cell/mL.  
Using Ficoll density separation, the detection limit was 1,000 spiked cells/mL of blood. 
Below that level, detection was not consistently reproducible. None of the control subjects 
exhibited E6 and E7 expression.  
The sensitivity of PCR in detecting circulating tumor cells based on E6 and E7 
oncogenes expression is one cell in the background of 106 cells [159].  
b) Cytokeratin 19 
Cytokeratin (CK) is an intermediate filament protein that participates in the formation of the 
cellular cytoskeleton. It is expressed only by epithelial cell types and is usually maintained 
during malignant transformation [173, 174]. Detection of CK19 in either blood or lymph nodes 
provides indirect evidence for the presence of cancer cells.  
In an experimental spiking model, the sensitivity of PCR for spiked CaSki cells 
following RBC lysis was 50 cells/mL with the ability to detect 1 cell/mL of blood based on the 
difference between the relative expressions of the lowest spiked cells and the control samples. 
Specifically, the X cycle threshold difference between the positive and the negative signals can 
be directly interpreted to a value of Y (log2 of Y) and used to be divided by 50 cells/mL to 
obtain a value of Z, which equal to one cell/mL. However, CK19 expression is not tumor-
specific and was detectable in control subjects. It was previously determined that CK19 
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transcripts can be detected in ≤20% of normal healthy individuals and/or those with benign 
disease [26]. Moreover, CK19 pseudogenes have been identified and could result in false 
positives [194, 195]. The primers used in our CK19 analyses were constructed to avoid detection 
of these pseudogenes.  
We postulate that if an appropriate cutoff median expression value is established for a 
normal expression level, then this marker may be used for CTC detection. Using RT-PCR with 
established cutoff value to detect CK19 transcript in breast cancer patients, 2.2% of healthy 
females were positive compared to 31% and 40% of those with early and metastatic breast 
cancer, respectively. Moreover, the CK19 expression levels were significantly higher in breast 
cancer patient compared to those in the control group [196].  
The sensitivity of PCR in detecting CTCs based on CK19 is one cell in the background 
of 106 cells [163].  
c) P16INK4A 
P16INK4A is cyclin dependent kinase (CDK) inhibitor that functions as tumor suppressor in the 
transition from G1/S phase. It binds CDKs and inhibits the phosphorylation of Rb to prevent the 
release of the E2F transcription factors [181, 182]. P16INK4A is indirectly overexpressed in 
cervical cancer as result of functional inactivation of Rb by the oncoprotein E7 and can be used 
as molecular biomarker for diagnosis [183].  
In experimental spiking model, the sensitivity of PCR in detecting spiked CaSki cells 
following RBC lysis was 50 cells/mL with the ability to detect 1 cell/mL of blood based on the 
difference between the relative expressions at the lowest spiked sample and control samples. 
Specifically, the X cycle threshold difference between the positive and the negative signals can 
be directly interpreted to a value of Y (log2 of Y) and used to be divided by 50 cells/mL to 
obtain a value of Z, which equal to one cell/mL.  
However, the marker is non-tumor specific and expression level increases in healthy 
individual with age and smoking [197-199]. The expression of p16INK4A is usually very low 
compared to cancer cell lines and, if appropriate cutoff median value is established, may be 
useful for the detection of CTCs.  
75 
 
3) Detection of CTCs in uterine cervical patients 
UCC tumor bank has been developed during laboratory experimentation to optimize detection 
techniques. Ficoll-Paque was used to enrich PBMC from the first six patients. As we determined 
that RBC lysis buffer was more sensitive than Ficoll-Paque for enriching tumor cells, and was 
used to process blood samples collected from future patients. Those whose primary tumors 
tested positive for HPV16 at the time of the diagnosis were subjected to qRT-PCR to detect 
CTCs. No patients with advanced-stage UCC had been recruited at the time this study was 
conducted. 
Six patients were at stage I and four patients had stage II disease. None of these patients 
tested positive for E6 or E7 transcripts in the blood. Those patients had early stage disease, 
which explain the negative result. Pao et al. used nested RT-PCR to detect E6 oncogene 
expression in the blood of 12/13 patients with metastatic UCC. In follow up by the same group, 
they were also able to detect HPV16/18 E6 transcript in 51% (18/35) of locally advanced stage 
disease. Fourteen patients were stage IIB and, of those, 42% were positive. However, one of the 
primers used in the first round of nested PCR and one in the second round could detect genomic 
HPV DNA. HPV DNA has been detected in the peripheral blood in 12-24% of patients with 
invasive UCC and 1.8% in patients with high-grade cervical lesions [200-203]. Detection of 
HPV DNA in the circulation can be result of shedding early apoptotic or necrotic tumor cells 
into the circulation and tumor cell engulfment by macrophages [204-206]. Using DD-RT-PCR 
with primers similar to those used in this experiment, 3/10 patients with recurrent disease were 
positive for E6 expression in their blood [162]. Two patients with distant metastasis had the 
highest CTC count. DD-RT-PCR demonstrated a sensitivity of 1 CTC for every 500,000 
PBMCs, and a sensitivity of 5 CTCs/mL of blood. The number of PBMC background drastically 
affected the sensitivity of the PCR. In our study, PBMCs were enriched with RBC lysis and 
subjected to qRT-PCR. However, we did not take into consideration the number of PBMCs, 
which could explain our negative result. An experimental spiking compared RBC lysis, standard 
Ficoll centrifugation, and modified gradient Ficoll centrifugation combined with 
immunomagnetic positive enrichment targeting EpCAM in detecting E6 and E7 using nested 
RT-PCR. In contrast to our finding, the latter was found to be the most sensitive with ability to 
detect 3.33 cells/mL of blood with consistent reproducibility compared to 13.3 and 5.33 
cells/mL for the former studies, respectively [161]. However, the addition of immunomagnetic 
76 
 
separation is factor that improved PCR sensitivity by eliminating the PBMC-derived RNA. The 
centrifugation force used to collect cells in RBC lysis protocol was 3000g compared to 1800g 
used in the other protocols, which could have resulted in cell membrane damage and RNA 
disintegration as result of RNase released from lysed RBCs. Moreover, the quantity of RNA 
used to synthesize the cDNA was based on volume rather than a known measured quantity. The 
sensitivity of PCR was inversely related to the amount of cDNA that was introduced into the 
reaction. Using the modified protocol combined with EpCAM positive enrichment, 3/13 patients 
with UCC were positive for E6/E7 expression. Two patients had stage IB and were positive for 
HPV16 E6/7 and the third patient had stage IIIA and was positive for HPV35 E6/E7. The 
remaining negative patients were of stage I disease and three of them had lymph node metastasis. 
The detection rate was 23% for the whole group, while for stage I disease only was 18.1%. 
Interestingly, all patients had HPV DNA detected in their blood.  
Using CK19, we were able to detect CTCs in two patients who had clinical stage II 
disease. The level of CK19 expression was 2-3 log higher than the negative control samples. 
Three patients had CK19 expression level similar to the negative control, and were thus 
considered negative. The detection rate of CTC using CK19 was 20% in all tested patients 
whereas in stage II disease the detection rate was 50% (2/4 patients). Using nested RT-PCR to 
detect CTCs through CK19 transcript, 21.4% of stage IB-IIB patients were positive. None of 
the healthy female controls were positive, while only 5.7% with benign gynecological disease 
was positive [163]. Mitsuhashi et al. used RT-PCR of EGFR mRNA to detect CTCs and 
compared it to CK19 expression. Notably, EGFR was expressed in 98% of primary tumors and 
6.3%, 31.3%, and 46.2% of stage I, II, and III/IV, respectively. None of the controls expressed 
EGFR. CK19 was detected in 77.8% of patients; however, 65% of the controls were positive as 
well [164]. Using qRT-PCR with established cutoff value to detect CK19 transcript in breast 
cancer patients, 2.2% of healthy female were positive while 31% and 40% patients with early 
and metastatic breast cancer were positive, respectively. Moreover, the level of CK19 expression 
was significantly higher in breast cancer patients compared to controls [196]. 
P16INK4A was expressed with similarly across control subjects and patients. No studies 
have been conducted to evaluate the usefulness of p16INK4A for the detection of CTCs in UCC. 
Other studies have used circulating tumor DNA in the detection of CTC p16INK4A and its aberrant 
methylation [207, 208]. We postulate if an appropriate cutoff median value is established, this 
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marker would be able to identify CTCs, as p16INK4A had a detection limit of 50 cells/mL in 
samples with the ability to detect to 1 cell/mL of blood.  
In summary, we demonstrated the ability of HPV E6/E7, CK19 and p16INK4A to detect 
CTCs using qRT-PCR in experimental spiking model and their detection limit. The sensitivity 
of PCR improved with the addition of either negative or positive magnetic enrichment. E6/E7 
are the most sensitive and specific markers to detect CTCs in experimental spiking model. CK19 
and P16INK4A had basal expression in control subjects and appropriate cutoff median expression 
values have to be established to identify CTCs.  
In UCC patients, CTCs were detected in 20% from all tested patients and 50% in stage 
II disease using CK19 gene expression. Those with negative result, six patients had stage I 
disease and two patients had stage II disease. This finding is in concordance with the reported 
literatures that range between 21-42% for stage 1B-II UCC patients. On the contrary, none of 
the tested patients had E6/E7 oncogenes expression. This group of patients had mainly stage one 
disease and low volume disease compared to other reported studies. However, two patients had 
CK19 gene expression detected while E6/E7 were negative. We postulate that CK19 gene 
expression is more abundant than E6/E7, which accounts for the contradictory finding. 
Specifically, there is 5-log difference between CK19 and E6/E7 genes expression in CaSki cell 
line. During the progression of oncogenic HPV-infected lesion, the number of viral genomes 
that integrates into to the host genome varies. For instance, CaSki cell line (HPV16-positive) 
has 60-600 estimated copies number of integrated HPV genome per cell; HeLa cell line 
(HPV18-positive) has 10-50 copies; and SiHa cell line (HPV16-positive) has 1-2 copies [209]. 
Additionally we did not account for the number of PBMC, which could be a factor that resulted 
in the contradictory finding. The average number of PBMC in one mL of blood is 5-7 millions. 
DD-RT-PCR demonstrated a sensitivity of 1 CTC for every 500,000 PBMCs and a sensitivity 
of 5 CTCs/mL of blood. The number of PBMC background drastically affected the sensitivity 
of the PCR and the detection of one cell in more than 500,000 PBMCs background was not 
possible using E6/E7 gene expression. Thus, negative or positive enrichment should be used to 
eliminate most of PBMC-derived RNA background to reduce the inhibitory effect on PCR 
reaction.    
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CONCLUSION  
Detection of circulating tumor cells is dependent on multiple factors including the rarity of these 
cells within the blood, the enrichment process, cancer cell heterogeneity, and detection 
techniques. Ficoll-Paque, a widely used density medium to enrich tumor cells, has low 
sensitivity in enriching CTCs with detection limit of 1,000 cells/mL of blood using qRT-PCR 
for HPV E6/E7 oncogenes expression with an average recovery of 50%. We demonstrated low 
recovery rate, inter- and intra-variation in recovery rate among operators, and interestingly, 
aggressive tumor cell lines had the lowest recovery rate. RBC lysis demonstrated superiority 
with minimal cell loss with recovery of >90%. HPV16 E6/E7 expression evaluated by qRT-
PCR is the most sensitive and specific marker to detect UCC cells at approximately 1 cell/mL 
of blood in an experimental spiking model. CK19 and p16INK4A had a similar detection limit to 
HPV oncogenes and can be used to verify the diagnosis provided a cutoff median expression 
value is determined for normal individuals. Both positive and negative enrichment using 
immunomagnetic improved PCR sensitivity by eliminating PBMC-derived background RNA. 
Positively enriched cells of high purity could be used to assess tumor genes expression; however, 
tumors of non-epithelial origin and those with low EpCAM expression resulting from EMT 
could not be detected. Negatively enriched tumor cells were less pure when compared to positive 
enrichment. Moreover, tumor cells that attached to and/or engulfed by macrophages were lost. 
In the early-stage UCC patients, CTCs were detected in 2/10 patients using CK19 gene 
expression. None of the patients had detectable HPV16 E6 and E7 expression. P16INK4A was 
expressed at a similar level across all samples. These finding suggest that CTCs are very rare in 
early UCC, in agreement with previous reports. 
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PERSPECTIVES  
Uterine cervical cancer tumor bank at CHUM has been developed recently and currently 
includes over 70 patients. Ten patients were tested for CTCs and two of them were positive for 
CK19, all of which had stage II disease. Six patients with stage I and one patient with stage II 
disease were negative for CK19, E6/E7 and p16INK4A. Our finding is compatible with the 
previously reported literature. To validate the ability of these markers to detect CTCs in UCC, 
metastatic UCC patients would be the best candidates to withdraw a definitive conclusion. 
Here, we report that HPV16 E6/E7 oncogene expression is sufficient to detect CTCs in UCC. 
However, other HPV oncogenic types can be included as well. To further optimize the PCR 
sensitivity, future patients should be enriched with RBC lysis combined with negative 
enrichment to eliminate PBMC background that could affect the PCR sensitivity. If preliminary 
data in UCC patients is encouraging and demonstrates the ability to detect CTCs, patients will 
be followed up with serial CTC detection to determine its prognostic significance. 
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